Interaction of small molecules with nucleic acid targets: from RNA secondary structure to the riobosome by Canzoneri, Joshua Craig
INTERACTION OF SMALL MOLECULES WITH NUCLEIC ACID 




























In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy in the 












INTERACTION OF SMALL MOLECULES WITH THEIR NUCLEIC 























Approved by:   
   
Dr. Adegboyega Oyelere, Advisor 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
 Dr. Stephen Harvey 
School of Biology 
Georgia Institute of Technology 
   
Dr. Nicholas Hud 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
 Dr. Roger Wartell 
School of Biology 
Georgia Institute of Technology 
   
Dr. Loren Williams 
School of Chemistry and Biochemistry 
Georgia Institute of Technology 
  
   





 The list of people that I owe thanks to for my current position in life is quite long, 
but I will highlight the most influential here. First and foremost, I would like to thank my 
advisor, Dr. Yomi Oyelere for the amazing opportunity to work in his lab. His steadfast 
sense of direction, understanding nature,  and vast knowledge of all things chemistry 
have been a huge inspiration to me, and have undoubtedly helped me to mature as both a 
scientist and as a person.  It is also his great passion for what he does that inspires me. 
The excitement seen in Dr. Oyelere’s expression when presented with new data has 
provided me with a ceaseless sense of accomplishment throughout my graduate career. 
Most importantly, it has been Dr. Oyelere’s confidence in me that has led me to my 
successes. He believed in my abilities even when I was unsure of myself, and I could 
never express enough how much that has meant to me. 
 I would also like to thank my committee members; Dr. Harvey, Dr. Hud, Dr. 
Williams, and Dr. Wartell. My interactions with them in the classroom as a young grad 
student, and in RiboEvo later in my graduate career, have been an absolute joy. The 
enthusiasm with which these gentlemen approach science has left a lasting mark on me. I 
must also thank them for the confidence they have had in me over the years, for it has 
allowed me to truly become confident in myself as a chemist. 
 Appreciation must also be given to my family and close friends. Even though they 
may not have fully understood exactly what I was doing in the lab, they always showed 
me support and praise.  
 iv
 Thanks are also due to my lab family, both past and present, in the Oyelere Lab. 
We have shared the greatest joys and the deepest sorrows together. The tragic loss of 
Dereck Benicewickz will forever be a reminder of just how precious life is. Despite this 
heartache, seldom a day passed in wing 3A where laughter was not heard from the 
Oyelere Lab benches, and for that I am most grateful. Each and every member holds a 
special place in my heart and I wish them nothing but the best. 
 I must also thank my wonderful future wife, Ms. Tiffany Livingston, for coming 
back into my world at exactly the right time and cheering me on during my final years of 
grad school. Her endless love, understanding and encouragement have been a catalyst in 
the progression of my life. 
 I would like to dedicate this thesis to my grandmother, Beverly Jean Sprinz. 
Grandma Bevy was diagnosed with stage 4 non-small cell lung cancer in December of 
2010. As of the completion of this manuscript in July of 2012, she is losing the battle 
against this horrible disease. Despite her pain, she has managed to always keep a smile on 
her face and a sense of humor about her. Her strength through this struggle will always 












TABLE OF CONTENTS 
Page 
ACKNOWLEDGEMENTS iii 
LIST OF TABLES viii 
LIST OF FIGURES ix 
LIST OF SCHEMES xi 
LIST OF SYMBOLS AND ABBREVIATIONS xii 
SUMMARY xiv 
CHAPTER 
1 Introduction 1 
1.1 RNA Structural Motifs Involved in Binding 1 
1.2 Targeting the Ribosome 12 
1.3 References 21 
2 Interaction of Anthracyclines with Iron Responsive Elements mRNAs 30 
2.1 Introduction 30 
2.2 Anthracycline Antibiotics 31 
2.3 Iron Metabolism and Regulation via Iron Responsive Elements 33 
2.4 Biophysical Characterization of Anthracycline/IRE RNA Interaction 35 
2.5 Discussion 49 
2.6 References 56 
3 Preferential Binding of Anthracyclines to DNA Mismatch Base Pairs 63 
3.1 Known DNA / Anthracycline Interactions 63 
3.2 Biophysical Characterization of Anthracycline / Hairpin DNA           
Interaction 66 
 vi
3.3 Discussion 78 
3.4 References 82 
4 Exploring the Ribosome with Novel Macrolide-Peptide Conjugates 92 
4.1 Architecture of the Ribosomal Exit Tunnel 92 
4.2 Peptolide Design and Synthesis 93 
4.3 In vitro Cell Extract Inhibition Assays 97 
4.4 Chemical Footprinting 99 
4.5 Discussion 105 
4.6 References 111 
5 Characterization of Novel Topoisomerase II / Histone Deacetylase             
Inhibitor Conjugates: Nucleic Acid Binding Properties 114 
5.1 Introduction 114 
5.2 Rational Design of TopoII / HDACi Conjugates 115 
5.3 In vitro HDAC Inhibition 121 
5.4 In vitro TopoII Decatenation 124 
5.5 In vitro Cell Growth Inhibition  126 
5.6 Intracellular TopoII Inhibition 129 
5.7 Cellular Localization 132 
5.8 Interaction of Conjugates With DNA and RNA  134 
5.9 Discussion 139 
5.10 References 142 
6 Molecular Architecture of Zinc Binding Small Molecules that Inhibit   
Splicesome Assembly 151 
6.1 Introduction 151 
6.2 Screening of Structurally Diverse HDACi for Splicing Inhibition 155 
6.3 Conclusions 167 
 vii
6.4 Materials and Methods 168 
6.5 References 170 
7 Conclusions and Future Directions 174 
APPENDIX A: Supplemental Information for CHAPTER 2 175 
APPENDIX B: Supplemental Information for CHAPTER 5 190 
VITA        191 
 viii 
LIST OF TABLES 
Page 
Table 2.1: Melting Temperature Data for IRE RNAs in the Absence and Presence of 
Anthracyclines 39 
Table 2.2: Apparent Dissociation Constants for DOX and IRE RNAs 43 
Table 3.1: Melting Temperature Data for DNA Mismatch Hairpins and                 
Anthracyclines 70 
Table 4.1: Peptolide IC50 Values For Cell Free Translation Inhibition Assays 98 
Table 5.1: In Vitro HDAC Inhibition of TopoII / HDACi Conjugates 123 
Table 5.2: Cell Viability Assay of TopoII / HDACi Conjugates 128 
Table 5.3: Melting Temperature Data and Stern-Volmer Constants for                     
TopoII / HDACi Conjugates and DNA 137 
Table 5.4: Melting Temperature Data for TopoII / HDACi Conjugates and RNA 137 
Table 6.1: Structure Activity Relationship and Splicing Inhibition of Novel Zinc   





LIST OF FIGURES 
Page 
Figure 1.1: Crystal Structures of B-DNA and A-RNA 3 
Figure 1.2: Crystal Structure of DOX Bound to DNA 4 
Figure 1.3: Crystal Structure of Cisplatin Bound to DNA  5 
Figure 1.4: Representative Secondary Structure Elements found in RNA 7 
Figure 1.5: Crystal Structure of tRNA 8 
Figure 1.6: Hammerhead Ribozyme Mechanism and Conserved Structural Features 10 
Figure 1.7: Diagram of the 70S Ribosomal Subunit 13 
Figure 1.8: Crystal Structure of Linezolid Bound to 50S Ribosome 16 
Figure 1.9: Representative Structures of the Macrolide Antibiotic Family 17 
Figure 1.10: Crystal Structure of Erythromycin and Telithromycin Bound to the 50S 
Ribosomal Subunit 18 
Figure 1.11: Position of Residue A2058 in Relation to Bound Macrolide 19 
Figure 2.1: Structures of IRE RNAs and Anthracyclines 34 
Figure 2.2: UV Melting Profile of IRE RNA and DOX 38 
Figure 2.3: Absorbance and Fluorescence Profiles and Stern-Volmer Plot for               
IRE RNA and DOX  41 
Figure 2.4: Job Plot Analysis of IRE RNA and DOX 44 
Figure 2.5: RNase T1 Footprinting of IRE RNA in Absence and Increasing   
Concentration of DOX 47 
Figure 3.1: Hairpin DNA Construct and Anthracyline Structure 64 
Figure 3.2: Circular Dichroism of Wild Type and Mutant Hairpin DNA in Absence       
and Presence of DOX 72 
Figure 3.3: Stern-Volmer Analysis of Hairpin DNA Constructs Bound to DOX 75 
Figure 3.4: Negative ESI-Mass Spectrometry of Hairpin DNA Bound to DOX 76 
 x
Figure 3.5: Relative Binding Percentages of DOX Bound to DNA as Determined by    
ESI-Mass Spectrometry 77 
Figure 4.1: Macrolide Binding Pocket 93 
Figure 4.2: Crystal Structure of Telithromycin Bound to Three Unique 50S       
Ribosomal Subunits 94 
Figure 4.3: Modification of Telithromycin to Yield Peptolides 95 
Figure 4.4: Synthetic Scheme for Peptolides 96 
Figure 4.5: DMS Chemical Footprinting Analysis of 23S rRNA with Primer 2180 103 
Figure 4.6: CMCT Chemical Footprinting Analysis of 23S rRNA with Primer 2180 104 
Figure 4.7: Crystal Structure Indicating Location of Footprinted Residue U1963         
With Respect to Bound Macrolide 108 
Figure 5.1: Structure of Representative Anthracycline Antibiotics 117 
Figure 5.2: Design of Dual Acting TopoII / HDACi Conjugates 118 
Figure 5.4: Topoisomerase II Decatenation of KDNA Assay of TopoII / HDACi 
Conjugates 125 
Figure 5.5: Intracellular TopoII Inhibition of TopoII / HDACi Conjugates Slot Blot 131 
Figure 5.6: Fluorescence Microscopy Demonstrating Cellular Localization of          
TopoII / HDACi Conjugates  133 
Figure 5.7: RNA and DNA Constructs Used to Determine Nucleic Acid Binding 
Characteristics of TopoII / HDACi Conjugates 134 
Figure 5.8: Stern-Volmer Plot of TopoII / HDACi Conjugates Bound to DNA 138 
Figure 6.1: Prototypic HDAC Inhibitor 155 
Figure 6.2: MINX pre-mRNA Splicing Inhibition Assay 157 
Figure 6.3: Restoring Splicing by Adding Zn to MINX Assay 165 
 xi
LIST OF SCHEMES 
Page 
Scheme 5.1: Synthesis of SAHA-based TopoII / HDACi Conjugates 119 












LIST OF SYMBOLS AND ABBREVIATIONS 
 
ATP  Adenosine Triphosphate 
BPE  Bisphosphate EDTA Buffer 
CD  Circular Dichroism 
CMCT  1-cyclohexyl-(2-morpholinoethyl)carbodiimide metho-p-toluene sulfonate 
DAU         Daunorubicin 
ddNTP  Dideoxy Nucleotide Triphosphate 
DMS  Dimethyl Sulfate 
DMSO  Dimethyl Sulfoxide 
DNA  Deoxyribonucleic Acid 
dNTP  Deoxy Nucleotide Triphosphate 
DOX  Doxorubicin 
DTT  Dithiothreitol 
EDTA  Ethylenediaminetetraacetic Acid 
erm  Erythromycin Ribosome Methylase 
ESI-MS  Electrospray Ionization Mass Spectrometry 
HDAC  Histone Deacetylase 
HDACi  Histone Deacetylase Inhibitor 
HHR  Hammerhead Ribozyme 
IRE  Iron Responsive Element 
IRP  Iron Regulatory Protein 
KDNA  Kinetoplast DNA 
LIN  Linezolid 
MMR  Mismatch Repair 
 xiii 
mRNA  Messenger RNA 
pre-mRNA Precursor mRNA 
PTC  Peptidyl Transferase Center 
RNA  Ribonucleic Acid 
RNAi  RNA Interference 
RNP  Ribonucleoprotein 
rRNA  Ribosomal RNA 
SAR  Structure Activity Relationship 
snRNP  Small Nuclear Ribonucleoprotein 
TBE  Tris Borate EDTA Buffer 
TEL  Telithromycin 
TopoII  Topoisomerase II 
tRNA  Transfer RNA 
UTR  Untranslated Region 













Nucleic acids have proven to be viable targets for small molecule drugs. While 
many examples of such drugs are detailed in the literature, only a select few have found 
practical use in a clinical setting. These currently employed nucleic acid targeting 
therapies suffer from either debilitating off-target side effects or succumb to a resistance 
mechanism of the target. The need for new small molecules that target nucleic acids is 
evident. However, designing a novel drug to bind to DNA or RNA requires a detailed 
understanding of exactly what binding environments each nucleic acid presents. In an 
effort to broaden this knowledge, the work presented in this thesis details the binding 
location and affinity of known and novel nucleic acid binding small molecules with 
targets ranging from simple RNA secondary structure all the way to the complex 
structure of ribosomal RNA. Specifically, it is shown that the anthracycline class of 
antineoplastics prefer to bind at or near mismatch base pairs in both physiologically 
relevant iron responsive element RNA hairpin constructs as well as DNA hairpin 
constructs presenting mismatched base pairs. Also characterized in this thesis is a novel 
class of topoisomerase II / histone deacetylase inhibitor conjugates that display a unique 
affinity for DNA over RNA. Finally, the novel class of macrolide-peptide conjugates, 
known as peptolides, are shown to retain potent translation inhibition of the prokaryotic 
ribosome. The binding pocket of the peptolides, including a crevice previously 
unreachable by macrolides that extends away from the peptidyl transferase center toward 
the subunit interface, is confirmed in detail via chemical footprinting of the 70S 
ribosome.  Overall, the identification of a novel binding site for the anthracycline class of 
 xv
drugs and the characterization of the two novel drug designs presented in this thesis will 
undoubtedly aid in the effort to design and discover new molecules that aim for nucleic 
acid targets. For example, the anthracycline derivative topoisomerase II / histone 
deacetylase inhibitor conjugates, with their differential mode of nucleic acid binding, 
may prove to have a unique side effect profile in a therapeutic application. The peptolide 
compounds also have the potential to be applied as novel antibiotics as they bind to an 
area of the prokaryotic ribosome unrelated to known macrolide resistance mutations. 
Furthermore, as a result of the observation of this thesis work that some peptolides also 
posses eukaryotic translation inhibition capabilities, they could prove to be useful in 
preventing the growth of rapidly proliferating eukaryotic cells such as plasmodium, 
leishmania, or tumor cells. Additionally, different head groups could be utilized in 
creating new peptolides; for example, an oxazolidinone antibiotic could be employed to 








CHAPTER 1: INTRODUCTION 
 
1.1 RNA Structural Motifs Involved in Binding 
 
 In recent decades, nucleic acids have been shown to be not merely the scribes of the 
genetic and proteomic code, but they have also been revealed to play crucial roles in regulating 
genes and gene products via interaction with a variety of ligands including other nucleic acids, 
proteins, metabolites, cofactors, enzymes, and small molecules (1-11). Prior to this realization, 
proteins were the main targets of a medicinal chemistry campaign to identify novel small 
molecules with therapeutic potential. With the successful sequencing of the human genome, 
hopes were high that all proteins in the human body could be identified and subsequently many 
new ones could become the target for the treatment of diseases. This, however, has not panned 
out as only 15% of the human proteome has been deemed drugable and only 207 proteins are 
targeted by current FDA approved small molecule drugs (12, 13). Many of these clinically 
successful drugs share the trait of mimicking a protein partner in a protein-protein interaction as 
their primary mode of action (14, 15). Due to the large surface area and relative complexity of 
these interactions, it has proven to be a very difficult endeavor to target proteins with small 
molecules for therapeutic application. This has emphasized the importance of being able to target 
the source of the protein product related to a disease state, the DNA and RNA encoding it, as a 
means of treatment.  There have been relatively few successful cases of directly targeting DNA 
in a clinical setting. The most notable success stories would be the alkylating antineoplastic 
agents such as nitrogen mustards, nitrosoureas, and alkyl sulfonates as well as the cisplatin and 
anthracycline families of chemotherapeutics (16-19). With an even more underwhelming 
representation is the effort to develop treatments exploiting RNA as the target, excluding of 





target specific nucleic acid sequences, the difficulty in delivering the small RNA constructs to 
the target has hindered its application in a clinical setting (20-21).  Efforts are concurrently 
underway by multiple labs to develop not only a clear understanding of how nucleic acids react 
and bind to small molecules drugs, but also to identify and characterize novel nucleic acid 
binders in both a high-throughput and a rationally-driven design basis (22-24).  
In order to facilitate this search for novel nucleic acid targeting small molecules, a 
thorough understanding of what a nucleic acid binding site has to offer to a small molecule is 
needed. This can be gleaned by examining the secondary and tertiary structures formed by doth 
DNA and RNA and by considering several examples of drugs that have successfully pinpointed 
nucleic acids in a clinical setting. DNA and RNA share a similar structure in that they both form 
a duplex of phosphate backbone linked nucleosides stitched together in a helical arrangement by 
base pairs between adjacent, anti-parallel strands.  However, due to the unique sugar pucker 
restrictions of RNA owing to its additional 2` hydroxyl group, duplex RNA in a physiological 
environment presents a much different helical structure in three dimensions than DNA (Figure 
1.1). The typical B-form DNA found inside the cell presents a wide yet shallow major groove 







Figure 1.1 A) Crystal structure of the typical B-DNA helix. B) Crystal structure of typical A-
RNA helix. (25, 26) 
 
 The width of the major groove allows for easy access to the hydrogen bond participant and pi-
stacking rich core of the DNA duplex by small molecules. The deep and narrow nature of the 
minor groove presents a hydrophobic and densely electronegative rift for small electropositive 
molecules. The binding of daunorubicyn (DAU), a member of the anthracycline class of anti-
tumor drugs that also includes doxorubicin (DOX), to B-DNA clearly illustrates the two main 
non-covalent binding modes of small molecules to a nucleic acid target: minor groove binding 






Figure 1.2) A) General skeleton of the anthracycline class of drugs; DAU X=H, DOX X=OH.   
B) Crystal structure of two molecules of DAU (sphere) bound to B-DNA helix (stick) (27). 
  
The flat, conjugated ring system of the aglycone moiety of DAU slips snuggly in between 
adjacent base pairs of the DNA helix (Figure 1.2B). It is this favorable intercalation that has been 
attributed to the anthracycline family’s strong binding preference for DNA (28-36). Further 
stabilizing the interaction, the amino sugar moiety is presented to the minor groove where it 
binds firmly via electrostatic interactions (27).  
An example of a covalent small molecule interaction with DNA can be found with the 
chemotherapeutic cisplatin (Figure 1.3). Cisplatin is a platinum containing molecule that upon 
administration looses one of its chlorine atoms to water displacement. This water molecule, also 
an excellent leaving group, allows the platinum atom to readily bind to bases in the DNA helix, 
preferably G residues. The second chlorine atom is subsequently displaced, causing an 
intrastrand cross link between adjacent G residues. This crosslinking causes a distortion of the 
helix (Figure 1.3B) that is recognized by the DNA repair pathway but cannot be undone, thus 





confined nature in the cell, wound tightly around histone complexes in the nucleus, has made it 
difficult to directly target with but a few successful clinical applications. Even the success stories 
such as anthracyclines and cisplatin are plagued by systemic toxicity and off-target side effects, 
thus leaving much room for improvement. 
 
 
Figure 1.3 A) Structure of Cisplatin B) Crystal structure of cisplatin (Pt is pink sphere near 
center) covalently bound to a B-DNA helix. Figure adapted from (37). 
 
Conversely, RNA is ubiquitous in both the nucleus and cytoplasm and readily accessible 
to small molecule invaders of the cell. However, a survey of RNA’s secondary structuring 
highlights a dissimilar topology to that of DNA described above. With its fixed   C-3` endo 
ribose pucker, RNA presents an A-form helix inside the cell (Figure 1.1B). Unique to the A-form 





groove, but recent results have indicated that it is too narrow to accommodate small molecule 
binding (38). This is unfortunate since the major groove is rich with small molecule luring 
functional groups along the Hoogsteen edges of the base pairs (39). The minor groove of the A-
form RNA helix is both shallow and narrow, thus appearing to be a less alluring interaction site 
for a small molecule ligand than the inviting grooves of the B-DNA helix.  
 The seemingly constrained and minor groove-inaccessible conformation of the A-RNA 
duplex helix is not indicative of its ability to form complex tertiary structures. In fact, RNA has 
the gymnastic ability to form some of the most complex binding motifs found inside the cell 
(39). It owes this flexibility to several key differences from its DNA counterpart. DNA for the 
most part exists as a duplex of individual strands. This dictates that the DNA always be paired to 
its compliment in what tends to be a very strict, canonical Watson-Crick base pairing fashion. In 
contrast, RNA exists almost entirely as a single stranded entity, save of course for its time spent 
paired with its molecular role model in a DNA:RNA hybrid. As a result of its inherent single 
strandedness, RNA is left to fold back upon itself in a complimentary fashion. Without a strict 
compliment for the RNA strand, very unique and complex structures arise from the lone RNA 
strand searching for its lowest entropic energy state with only itself, water, and a few metal ions 
to rely on. Some of the most commonly observed secondary structures found to be conserved in 






Figure 1.4 Some of the conserved and unique secondary structures found in RNA-ligand 
interactions. A) hairpin loop B) single base bulge C) mismatch bulge D) multi stem junction 
 
 Despite its limiting features as a strict A-form helix, the building blocks presented in 
Figure 1.4 are just a few of the features that RNA employs to engineer incredibly complex 
secondary and tertiary structure. The hairpin loop allows the RNA strand to make sharp turns 
back onto itself, the bulges allow for symmetrical and asymmetrical disregard of any unruly 
bases not wanting to pair, and the multi-way junction allows multiple, distinct regions of 
functionality to bud and branch out of the same single strand of RNA (39, 40). Another factor 
contributing to the structural plasticity of RNA is the high incidence and tolerance of 
mismatched base pairs. Unlike DNA, RNA does not have a housekeeping repair pathway to 
clean up mismatched pairs. While a base mismatch in DNA has the possibility to corrupt the 
genome and must be corrected swiftly, the mismatch pair in RNA is employed as a point of 
flexibility in the tertiary structure. In fact, mismatch pairs are often also a conserved feature in 
RNA recognition motifs (41). The base-pair mismatch distorts the shape of the A-RNA helix. 





major groove and opening up an electronegative pocket offering an inviting home to any number 
of small molecule binders.  
An elegant example of all of these highly emancipating structural features coming 
together to form a macromolecule important to all known life can be found in the structure of 
transfer RNA (tRNA). When the crystal structure of yeast tRNAPHE was solved for the first time 
in 1974 it revealed an incredible number of structural features made from only a 76-nt long RNA 
strand (42, 43). As crystallographic resolution improved over the coming decades, even more 
structural characteristics were gleaned from the similar E. coli tRNAPHE (Figure 1.5). 
 
Figure 1.5 Cyrstal structure of tRNAPHE flaunting its many structural motifs unique to RNA 
(44). 
 
In this single, relatively short tRNA there exist a number of secondary and tertiary interactions 
serving to hold the oligo in exactly the correct orientation to recognize and selectively deliver 





of these interactions include non-canonical base pairs, hairpins, 10 modified bases, and a 
complex three way stem junction held together by a number of base-triple pairs (44). 
Additionally there are a number of water molecules and divalent Mg2+ ions helping to stabilize 
tertiary interactions (44). It is truly remarkable to recognize just how many special building 
blocks were taken from the RNA engineering tool kit to create and conserve an RNA motif 
capable of recognizing its binding partner with such high fidelity.  
 An equal marvel of RNA structural complexity and ligand recognition can be found in 
the enzymatically active class of RNAs known as ribozymes. Prior to the discovery of the first 
ribozymes, enzymatic ability had been relegated solely to protein enzymes. It was the discovery 
of this class of self cleaving RNA structures that opened the doors for the RNA world theory; it 
was now possible for RNA to posses characteristics of both the chicken and the egg (the encoder 
of heredity and the enzymatic catalyst) in the long-lived debate over which came first in the 
origin of life, RNA or DNA. It was the complex tertiary structures observed in crystal structures 
of tRNA that led to the hypothesis that this was indeed feasible as early as the late 1960’s. Proof 
did not come until the late 1970’s via work by Thomas Cech involving a self-splicing RNA 
fragment and work by Sydney Altman on the discovery of the auto-catylytic RNase P (45-47). 
Cech and Altman shared the 1989 Nobel Prize in Chemistry for their contribution to the 
discovery that RNA was not just a molecule of heredity, but that it was more importantly a 
biocatalyst (48). Ribozymes have been shown to be capable of several types of enzymatic 
reactions without the need for cofactors such as adenosine triphosphate (ATP). The most 
common of these enzymatic capabilities is the cleavage of its own phosphodiester backbone via a 
transeserification reaction, as found in, for example, the hammerhead ribozyme (HHR) family 





to be conserved in one form or another in all three boughs of the tree of life (49). A close look at 
the secondary and tertiary structure of HHRs again highlights the complexity attainable by the 
ribonucleic acid polymer (FIG 1.6B&C).  
 
Figure 1.6 A) The self catalyzed SN2 mechanism by which the ribozyme cleaves its own 
backbone. B) The minimal structure of the HHR catalytic core. The site of cleavage is indicated 
by the arrow. C) The three types of complete HHR configurations known to be active under 
physiological conditions. Figure adapted from (49). 
 
 
 Of the known types of existing HHR catalytic cores, the same general secondary and 
tertiary design elements remain constant: three helical segments held in precise alignment with 
respect to one another via tertiary interaction between conserved residues. While the minimal 
catalytic core has been shown to be active in vitro (Figure 1.6B), it has been shown that in vivo 





function (50-51). This is a testament to the absolute precision with which these ribonucleic acid 
based enzymes have evolved. Perhaps the most awe inspiring feat of RNA secondary structure 
can be found in what amounts to the most sophisticated ribozyme found in life, and the subject of 








1.2 Targeting the Ribosome 
 
 The most successfully targeted nucleic acid to date has undoubtedly been ribosomal RNA 
(rRNA). In fact, nearly all current FDA approved RNA targeting therapeutics are antibiotics 
specifically targeting the RNA component of the bacterial ribosome (52-54). The ribosome is 
one of the most sophisticated and complex macromolecular machines ever discovered and thus 
may seem to be a daunting target for any rationally designed therapeutic.  However, with a 
thorough understanding of its components, assembly, and function coupled with an appreciation 
of previously examined rRNA-targeting drugs, the ribosome becomes much less intimidating 
prey for a stalking small molecule. The ribosome is the cell’s protein assembly line and is 
required for life across all three branches of the phylogenetic tree. This peptide production 
facility reads the triplet code embedded in the messenger RNA (mRNA), which has been 
transcribed from genomic DNA, and utilizing a multitude of cofactors diligently adds each 
additional amino acid residue to a growing nascent peptide chain utilizing tRNA as its molecular 
supplier of charged amino acids. While the catalytic core of the ribosome has very high 
conservation amongst all life forms, the composition and overall structure of the entire ribosome 
varies between archaea, eukaryota and bacteria. As the bacterial ribosome is the target of the 
antibiotics that will be discussed later, only its structure will be detailed here.  
 The prokaryotic ribosome in its entirety is known as the 70S unit, owing its name to the 
particle’s sedimentation coefficient in Svedberg units (S). This 70S ribosome is comprised of 
two smaller components known as the 50S and 30S subunits.  The 50S subunit consists of about 
30 ribosomal proteins as well as the 5S and 23S rRNA strands while the 30S subunit contains the 







Figure 1.7 Model detailing the relative positions of all major components of the 70S ribosome. 
Figure adapted from (55). 
 
 
The interface between 50S and 30S subunits is made almost entirely from rRNA and serves as 
the catalytic core of the ribosome. The 30S subunit is responsible for binding to the mRNA and 
subsequently proof reading each added amino acid. It is the purpose of the 50S subunit to serve 
as the site of peptide bond formation. This catalytic core, contained mostly in the 50S but 
extending into the 30S as well, is comprised of three distinct binding sites for incoming tRNAs: 
the A-site, P-site, and E-site. These three positions and the surrounding area are known together 
as the peptidyl transferase center, or PTC. The A site of the PTC serves as the premier binding 





this inbound tRNA is the P site, where the peptidyl transfer and bond formation will actually 
occur. The tRNA’s bound amino acid residue is ligated to the growing nascent polypeptide. Once 
relieved of its passenger, the tRNA then enters the E site where it exits the PTC and ribosome. 
To accommodate the structural rearrangements necessary for tRNAs to move from one site to the 
next, a large scale, concerted shift in overall ribosomal structure causes a ratcheting movement of 
the 50S and 30S subunits with respect to one another. As tRNAs shuttle in and out of the 
ribosome creating an ever longer peptide, the growing polypeptide makes its own egress from 
the ribosome through a long narrow passage in the 50S subunit known as the exit tunnel. A 
detailed understanding of the interworking of the ribosome is a relatively new revelation. It was 
not until 2000 that several high resolution crystal structures were solved simultaneously (56-59). 
Venkatraman Ramakrishnan, Thomas Steitz, and Ada Yonath shared the 2009 Nobel Prize in 
Chemistry for contributions allowing this intimate glimpse into the ribosome (60). 
 Once the structural specifics of the target are known it is then instructional to look at 
drugs that have successfully targeted rRNA.  With the many moving parts that are perfectly 
synchronized like tight fitting cogs in the impressive macromolecular machine of the ribosome, it 
is clear that a small molecule binding anywhere in the machinery could prove to be disastrous to 
the fidelity of the translational process. In fact, there exist several examples of clinically utilized 
antibiotic families that inhibit translation by doing exactly that, binding to the ribosome and 
stalling the gears. Two examples of more recent, broad spectrum antibiotics targeting rRNA of 
penicillin resistant bacteria can be found in the oxazolidinone and anthracycline families of 
drugs. Linezolid (LIN), the premier member of the oxazolidinone class of antibiotics, gained 
FDA approval for treatment of severe infections resulting from antibiotic resistant, gram-positive 





oxazolidone ring decorated with an acetamedomethyl tail moiety having an S-configuration 
(Figure 1.8A). Early on it was discovered that Lin owes its strong bacteriostatic nature to the 
ability to inhibit the initiation step of protein synthesis (62). By binding to the 50S subunit of the 
ribosome prior to ribosomal assembly, LIN affectively prevents the binding of the large and 
small subunits together along with tRNAfMet, thus preventing initiation. Looking to the crystal 
structure of LIN bound to the 50S subunit it becomes apparent why the small molecule has found 
such a suitable binding pocket amongst the rRNA (63).  As can be seen in Figure 1.8B, the ring 
systems of LIN nestle in amongst the bases of the 23S rRNA strand yielding 5 van der Waals 
interactions as well as a direct hydrogen bond to residue G2540.  The stacking of C2487, LIN, 
and U2541 is an excellent example of pi-pi stacking contributing to the binding affinity of a 
small molecule for RNA. In Figure 1.8B the binding position of a P-site binding analogue, CCA-
N-acetylphenylalanine (CCA-Phe), can also be seen. Using CCE-Phe as a landmark it becomes 
clear that LIN is binding in the direct vicinity of the A-site. This interference in the heart of the 
PTC is what leads to LIN’s ability to inhibit prokaryotic protein synthesis. Further studies have 
also indicated that LIN has the ability to bind in the P-site and directly interact with the first few 







Figure 1.8 A) Structure of Linezolid (LIN).  B) Crystal structure of LIN bound to the 50S 
subunit of Haloarcula marismortui. Labeled residues indicate positions of van der Waals 
interaction with the LIN molecule. The dashed line denotes a hydrogen bond to G2540. Figure 
adapted from (63). 
 
 
 While the oxazolidinone family has only one FDA approved drug in LIN, the much more 
clinically applicable macrolide class of antibiotics boasts a long list of approved compounds 
including azithromycin, clarithromycin, erythromycin and telithromycin. These and other 
macrocyclic antibiotics have been widely used to treat gram-positive bacterial infections across 
the globe for almost 60 years (65). Unique to this class of compounds is their tissue selective 
accumulation in the lungs, making them ideal for treating infections of the respiratory tract. 
Macrolide antibiotics share a similar macrocyclic skeleton, found in 13-17 member varieties, and 
have various sugars and other functional groups attached as appendages (Figure 1.9). Common 
to all members of the macrolide family is their binding location in the prokaryotic ribosome 





30S subunits directly adjacent to the PTC A- and P-sites (Figure 1.10). This site of interaction 




Figure 1.9 Representative structures of the macrolide class of antibiotics. 
 
It is this high affinity binding to an rRNA target so close to the PTC, effectively blocking the exit 
tunnel, that has made the macrolide class of drugs so crucial to human health in recent decades. 
A testament to the specificity of this small-molecule / RNA interaction can be found in the most 






Figure 1.10 Crystal structures of erythromycin (green) and telithromycin (pink) bound to the E. 
coli 50S subunit. Figure adapted from (73). 
 
 Macrolide resistance in certain bacterial strains was observed soon after the clinical 
introduction of erythromycin in the 1950’s (65). It was later understood that the mechanism 
behind this resistance was the bacteria’s ability to methylate its own ribosome via a set of genes 
known collectively as the erythromycin ribosome methylase (erm) genes (66). Utilizing the 
enzymes encoded in the erm gene, bacteria can selectively methylate the 23S rRNA. One such 
modification that proves to be highly detrimental to macrolide binding is a dimethylation of 
residue A2058 (66). The adenosine at position 2058, according to E. coli numbering, is directly 
adjacent to the macrolide binding pocket and even participates in van der Waals interaction with 
the macrolide (Figure 1.11). It is this intimate proximity to the bound macrolide that makes the 





strains of bacteria. The extra CH3’s sterically preclude the macrolide from being able to bind to 
its designated pocket in the ribosome. Similar seemingly miniscule mutations to the 23S rRNA 
have also been shown to lead to oxazolidinone resistance in a similar fashion (67-72). 
 
 
Figure 1.11 Crystal structure of erythromycin bound to the 50S subunit. Interaction with A2058 
is crucial to erythromycin’s ability to bind to the ribosome (73). 
 
 
 Of the strains of bacteria found in the hospital environment around the world, up to 75% 
of them (depending on geographical local) are both penicillin- and erythromycin-resistant (74). 
This staggering percentage, coupled with the fact that only three new classes of antibiotics have 
been approved by the FDA in the last 30+ years, intensifies the urgency with which novel rRNA 
targeting small molecules must be designed or discovered. Additionally, design of nucleic acid 
targeting small molecules as a whole could benefit greatly from a more thorough understanding 
of exactly what creates, and what disrupts, a suitable binding environment in DNA and RNA. It 





These compounds include known and novel, rationally designed, small molecule drugs. Detailed 
in this thesis is the characterization of a never before described binding preference of 
anthracyclines for mismatch GU pairs in biologically critical RNA structures, a similar 
investigation of the preference of anthracyclines for mismatches in DNA, and the rational design 
and characterization of a novel class of anthracycline / histone deacetylase conjugate class of 
small molecule drugs. Also detailed in this thesis is the design, synthesis, and target validation of 
a novel class of macrolide / peptide conjugates designed to interrogate the binding environment 
of the ribosomal exit tunnel. It is with the utmost intention that the work presented in the 
following pages will serve to enrich the knowledge of nucleic acid binding small molecules with 
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CHAPTER 2: INTERACTION OF ANTHRACYCLINES WITH IRON 
RESPONSIVE ELEMENT mRNAs 
 
This work was published by Joshua Canzoneri and Adegboyega Oyelere in Nucleic Acids 





Double-stranded sections of mRNA are often inviting sites of interaction for a wide 
variety of proteins and small molecules. Interactions at these sites can serve to regulate, or 
disrupt, the homeostasis of the encoded protein products. Such ligand target sites exist as 
hairpin–loop structures in the mRNAs of several of the proteins involved in iron homeostasis, 
including ferritin heavy and light chains, and are known as iron responsive elements (IREs). 
These IREs serve as the main control mechanism for iron metabolism in the cell via their 
interaction with the iron regulatory proteins (IRPs). Disruption of the IRE/IRP interaction could 
greatly affect iron metabolism. Here, we report that anthracyclines, a class of clinically useful 
chemotherapeutic drugs that includes doxorubicin and daunorubicin, specifically interact with 
the IREs of ferritin heavy and light chains. We characterized this interaction through UV 
melting, fluorescence quenching and drug–RNA footprinting. Results from footprinting 
experiments with wild-type and mutant IREs indicate that anthracyclines preferentially bind 
within the UG wobble pairs flanking an asymmetrically bulged C-residue, a conserved base that 
is essential for IRE–IRP interaction. Additionally, drug–RNA affinities (apparent Kds) in the 
high nanomolar range were calculated from fluorescence quenching experiments, while UV 
melting studies revealed shifts in melting temperature (∆Tm) as large as 10°C. This 
anthracycline–IRE interaction may contribute to the aberration of intracellular iron homeostasis 






2.2 Anthracycline Antibiotics 
 
 Daunorubicin (DAU), the first member of the anthracycline antibiotic family, was 
isolated from the Streptomyces peucetius soil bacterium in 1963. Soon after, the incredibly 
potent antineoplastic ability of DAU and its analogs, including its 14-hydroxylated variant 
doxorubicin (DOX), was noted in cancerous cell cultures (1). The antineoplastic nature of the 
compounds was at the time attributed to their ability to inhibit nucleic acid metabolism. It was 
observed that anthracyclines not only bound to nucleic acids but they also greatly inhibited the 
synthesis of both DNA and RNA (2, 3). The anthracycline class of drugs quickly entered clinical 
trials in the mid to late 1960’s, they were subsequently granted FDA approval, and they remain 
the cornerstone of clinical treatment of leukemia, lymphoma, solid tumors and Hodgkin’s disease 
(4). However, the clinical use of anthracyclines is limited by the occurrence of both chronic and 
acute cardiotoxicity that can often lead to cardiomyopathy, myocardial infarction and congestive 
heart failure (4-6). The mitigation of these often fatal side affects is of high interest and many 
attempts have been made to characterize the mechanism of anthracycline cardiotoxicity. 
However, there is much disagreement on this point in the literature. Theories include the 
suppression of transcription factors, production of reactive oxygen species, free radical-induced 
oxidative stress, decreased levels of intercardiac protective proteins and impaired intracellular 
iron handling and homeostasis (7-15). Elegant attempts have been made to tie all of the popular 
pathways listed above into a single complex model for anthracycline cardiotoxicity (16). 





elucidated in order to rationally design new therapeutic options for the successful treatment of 





2.3 Iron Metabolism and Regulation via Iron Responsive Elements 
 
 The iron responsive elements (IREs) of proteins involved in iron metabolism serve as the 
premier regulatory site of translation due to their unique tertiary structure. IREs are ≈30-nt long 
hairpin–loop structures in the untranslated regions (UTRs) of several iron metabolism proteins 
including both ferritin subunits (Figure 2.1), ferroportin and the erythroid isoform of 
aminolevulinate synthase, eALAS (17,18) The structure and sequence of IREs is highly 
conserved throughout all of the animal kingdom including early metazoan (19). The homeostasis 
of IRE-containing mRNAs is regulated by the iron-dependent availability of the IRP proteins 
(17). Ligand interaction in the UTRs of mRNA can serve to stabilize or destabilize the mRNA, 
and thus increase or decrease translation. In general, binding of a protein or small molecule in the 
5`-UTR inhibits translation by deterring the association of translation factors and preventing the 
assembly of the ribosome. Conversely, the binding of a ligand in the 3`-UTR upregulates 
translation by protecting against nuclease degradation (17). In the case of IRE–IRP interaction, at 
low intracellular iron concentrations, IRP1 is converted into its active binding state through the 
dissociation of its 4Fe-4S cluster. This active state then binds to the 5` IRE of ferritin heavy and 
light chain mRNAs, serving to downregulate translation and reduce the iron-storage capacity of 








Figure 2.1 (a) Human ferritin H-chain IRE 5_ UTR, (b) human ferritin L-chain IRE 5_ UTR, (c) 
anthracyclines investigated in this report, X=OH, doxorubicin; X=H, daunomycin. 
 
 
 The antitumor affects of anthracyclines are attributed to the ability of the molecules to 
inhibit topoisomerase by intercalating DNA, and the specifics of this interaction are very well-
characterized (20-28). However, the ability of these drugs to intercalate double-stranded RNA 
has largely been neglected in the literature. It has previously been observed that anthracyclines 
cause an imbalance in the regulation of IRP and its binding to IREs, but it has yet to be 
investigated whether this perturbation is a direct result of anthracyclines interacting with the 
IREs (11, 12). Toward unraveling the mechanism of anthracycline induced disruption of IRE 
binding to IRP we investigated the possibility of a direct interaction between anthracyclines and 
IREs harbored at the 5`-UTR of ferritin heavy and light chain mRNAs. A direct interaction of a 
small molecule, such as an anthracycline, with the IRE could change the tertiary structure of the 






2.4) Biophysical Characterization of Anthracycline/ IRE RNA Interaction 
 mRNA sequence selection and preparation 
The mRNA sequences of the human proteins of interest were retrieved from the Entrez 
Nucleotide Database (www.pubmed.org). The UTRs of these mRNA sequences were identified, 
and the folding of these sequences was modeled in the RNAstructure Version 4.3 program 
(rna.urmc.rochester.edu/rnastructure.html). The resulting secondary structures were surveyed to 
identify hairpin loop structures. The isolated sequence of the loop and stem region of these 
structures, on average 30 nt in length, was then folded via the RNAstructure program once again 
to ensure that the secondary structure was maintained in the absence of the rest of the sequence 
(Figure 2.1). The mRNA sequences of these structures were purchased from Dharmacon 
Research Inc., Lafayette, CO, deprotected according to the manufacturer’s protocol, and their 
purity was verified via denaturing urea polyacrylamide gel electrophoresis. RNA concentrations 
were determined by UV-vis spectroscopy in 1 cm path length quartz cuvettes using the molar 
extinction coefficients provided by Dharmacon. 
UV-vis melting and absorption experiments 
UV melting experiments were performed in the absence of drug and in the presence of 
DOX or DAU at final drug concentrations of 5 µM and 20 µM. RNA and drug complexes were 
formed by the addition of an aliquot of stock drug solution in DMSO to a volume of RNA in 
BPE buffer (6mM Na2HPO4, 2mM Na2H2PO4, 1mM EDTA, pH 7.1). The mixture was 
allowed to equilibrate for at least 20 min at 4°C to ensure complete association. The drug stock 
was prepared so that upon reaching the desired concentration of drug, the amount of DMSO in 
the sample was no >1% of the total volume. For absorption studies, a constant concentration of 





measured over the range of 400–600nm on a Cary 50 Bio UV-vis spectrophotometer. Melting 
studies were performed over a temperature range of 25–90°C, using a melting rate of 1°C/min 
and data were collected every half degree. In order to favor hairpin formation and avoid self-
association, constructs were heated at 99°C for 1 min, then slowly cooled (1°C/min) to 10°C 
prior to being melted from 25°C to 90°C (29). For melting experiments, absorbance was 
measured at 260 nm, the temperature was controlled with a Quantum Northwest TC 125 
temperature control unit, drug concentration varied between 5 and 20 µM, and the concentration 
of RNA was held constant at 2.5 µM. The Tm was taken as the midpoint of the melting transition 
as determined by the maxima of first derivative plots. An example of the first derivative plots for 
ferritin H-chain IRE RNA in the absence and presence of both DOX and DAU can be found in 
the Supplementary Material (Supplementary Figure S1). All Tms were reproducible to within 
±1°C. Repeated recording of heating and cooling profiles indicates that no hysteresis occurs in 
the absence or presence of ligand.  
Fluorescence quenching experiments 
Quenching of the drug’s natural fluorescence upon binding to RNA was monitored via 
titrations of a constant concentration of drug (7 µM) with RNA of increasing concentration (0.1–
20 µM). Quenching experiments were performed in a 96-well black microplate following the 
protocol described by Hergenrother et al. (30). Fluorescence emission at 556nm was recorded on 
a Molecular Devices SpectraMAX Gemini microplate reader after excitation at 480nm and 
485nm for DOX and DAU respectively. All experiments were repeated at least four times. The 
data collected in the fluorescence quenching titrations was fit to a second-order decay curve 






Where b is the apparent dissociation constant, x is the RNA concentration and a is the asymptotic 
limit. Fluorescence quenching plots and curve fits are available in the Supplementary Material. A 
stock solution of 4M NaCl in BPE buffer was diluted with BPE to achieve the various salt 
concentrations listed in the paper (31). 
RNase T1 footprinting 
The protocol for drug–RNA footprinting was adapted from previously reported methods 
(32). RNA constructs were 5`-end-labeled with γ-32P ATP (PerkinElmer, Waltham, MA) 
utilizing T4 polynucleotide kinase (Invitrogen, Carlsbad, CA) according to the manufacturer’s 
protocol. Labeled RNA (1.25 µM), unlabeled RNA (11.5 µM) and drug (1–20 µM) were 
combined in a final volume of 9 µl of footprinting buffer (11mM Tris–HCl, pH 7.0) and were 
allowed to equilibrate for 30 min at 25°C. The equivalent of 1U of RNase T1 enzyme (USB) was 
added and allowed to proceed for 10 min at 25°C. The reaction was quenched by the addition of 
5 µl of urea loading buffer (8M urea, 20mM EDTA and 2mM Tris, pH 7.5). Samples were then 
heated at 95°C for 5 min, and 11 µl of each sample was run on a 12% denaturing acrylamide gel 
for 90 min at 290 V. The gel was then dried, exposed to an IP plate (Fuji Film) and was 
visualized on a Fuji Film FLA-3000 IP plate scanner. Quantification of band intensity was 
performed with the Fuji Film program Multi Gauge version 3.0 utilizing profile quantification in 











UV melting and absorbance experiments 
The magnitude of ligand-induced change in nucleic acid Tm [ ∆Tm = Tm (RNA + ligand) - 
Tm(RNA)] is an indication of the affinity of the ligand for the nucleic acid target. Hence, we 
performed UV melting experiments to obtain the first indication of a direct association between 
the drugs and the IRE RNAs. The UV melting curves of both ferritin H-chain and L-chain IREs 
(Figure 2.2) display bi-phasic melting profiles in the absence and presence of drug.  
 
 
Figure 2.2 Overlay of the melting profiles of (a) ferritin H-chain mRNA and (b) ferritin L-chain 
mRNA in the absence (solid) and presence (dashed) of 20 µM DOX. 
 
 
The higher temperature transition (Tm=61°C) is a minor transition and was found to remain 
constant under all conditions. The lower temperature transition revealed a concentration-
dependent increase in Tm in the presence of DOX and DAU. The observed ∆Tm for all construct 
and drug combinations are presented in Table 2.1. It was found that the addition of drug to the 
IRE RNAs caused an increase in Tm not only in a concentration-dependent manner but also in a 
drug-dependent manner, with DOX consistently causing a more substantial shift than DAU 





and structure of the constructs led to a graded degree of Tm shift in response to the presence of 
drug. In the presence of 20 µM DOX, both the ferritin heavy and light IREs produced a ∆Tm of 
around 10°C (Table 2.1). Comparatively, the HIV-1 TAR RNA construct (33, 34), which is also 
a hairpin-loop structure that has been shown to interact with small molecules, produced a 
maximum shift of 5°C under the same conditions (data not shown).  
 
Table 2.1 The average ∆Tms observed for all drug and IRE combinations 
 
 
Guided by the results from the RNase footprinting experiments on wild-type IREs (see 
details below), mutations were made to the native H-chain IRE that altered or removed certain 
structural features associated with drug binding and recognition (35, 36). We constructed four 
point mutants designated U6C-IRE, C8A-IRE, U10C-IRE and G23I-IRE (I=inosine) with 
mutations at nucleotide positions 6, 8, 10 and 23, respectively; and one double mutant designated 
U6C-U10C-IRE, bearing double mutations that replaced the two UG pairs with CG pairs. These 
mutations were predicted by RNAstructure to preserve the IRE secondary structure. The 
difference in ∆Tm between these mutants and the wild-type indicated the importance of both UG 
wobble base pairs found in the ferritin IRE. The observed ∆Tm for the double mutant, U6C-
U10C-IRE, which replaces both UG wobble base pairs, was 5.5°C and 1.5°C in the presence of 
20 µM DOX and DAU, respectively. For the G23I-IRE mutant, the magnitudes of the observed 
∆Tm are slightly higher than that of the wildtype for both DOX and DAU at all concentration 





IRE, mutants in which one of the UG pairs is replaced with a CG, have identical ligand-
dependent ∆Tm. However, their observed ∆Tm is about 3°C less than that observed with the wild-
type RNA in the presence of 20 µM DOX.  
Figure 2.3a shows the changes that occur in the absorption spectrum of DOX in the 
visible region during the titration of a fixed concentration of DOX with increasing concentrations 
of the wild-type H-chain IRE. The resulting absorbance profile of DOX yielded two distinct 
absorbance maxima at ≈ 472nm and 499nm and a marked bathochromic shift was observed for 
both peaks resulting in a ∆λ of 5nm and 10 nm, respectively. Additionally, a hypochromism of 







Figure 2.3 (a) Absorbance profiles of 7 µM DOX in the presence of (from 1 to 6) 0, 0.5, 1.0, 2.5, 
7 and 20 µM ferritin H-chain IRE RNA. (b) Fluorescence profiles of the titration of 7 µM DOX 
with (from 1 to 8) 0, 1, 1.5, 2.5, 5, 7, 10 and 15 µM ferritin H-chain IRE RNA. (c) Stern–Volmer 
plot of 7 µM DOX with ferritin H-chain IRE RNA at the indicated temperatures. (d) Stern–
Volmer plot of 7 µM DOX with ferritin H-chain IRE RNA in BPE of the following Na+ 
concentrations: 16mM (filled diamond), 46mM (open diamond), 116mM (filled square), 216mM 
(open square) and 516mM (filled circle). Each Stern–Volmer plot was obtained from an average 









The natural fluorescence of DOX and DAU upon excitation was monitored as they were 
titrated with increasing amounts of RNA. The fluorescence spectra show a quenching of DOX 
fluorescence signal upon titration with IRE RNA (Figure 2.3b). The decay curves of the 
fluorescent signal were fitted, and apparent Kds were calculated. It is important to note that this 
apparent Kd is a total dissociation constant, and does not differentiate between the contribution of 
direct drug binding (e.g. intercalation) and the contribution of electrostatic interaction due to the 
charged nature of the anthracycline molecule. The apparent Kds and associated standard errors of 
RNA constructs are presented in Table 2.2. Fluorescence quenching data at 25, 28, 30 and 35°C 
was used to perform a Stern–Volmer analysis (31, 37, 38) of ferritin H-chain IRE RNA 
quenching DOX according to the equation: 
I0/I = 1 + KSV [Q] 
Where I0 and I are the fluorescence intensities in the absence and presence of RNA, respectively, 
[Q] is the concentration of quencher (RNA) and KSV is the dynamic quenching constant related 
to the bimolecular collision process. For the quenching experiment at 25°C, this analysis 
revealed a linear relationship between I0/I and [Q] (Figure 2.3c). The linearity of the Stern–
Volmer plot indicates that the mode of quenching is either collisional or static. Collisional and 
static quenching can be distinguished by their different dependencies on temperature. An 
increase in temperature leads to an increase in the diffusion constant of the quencher and will 
result in an increase in collisional quenching. In contrast, an increase in temperature will lead to 





quenching for a static quencher (38). To identify the quenching mechanism, we repeated the 
quenching experiments at 25, 28, 30 and 35°C. Stern–Volmer analysis of the resulting data 
revealed linear relationships between I0/I and [Q] and also showed that the KSV is inversely 
correlated with temperature (Figure 2.3c). Based on this result, it could be concluded that the 
probable quenching mechanism of the DOX-H-chain IRE–RNA complex is initiated by static 
quenching (37, 38). 
 





To determine the drug/RNA stoichiometry, we use the fluorescence quenching data to 
construct Job plots (Figure 2.4) (39, 40). The x-axis of the Job plot, labeled as the mole fraction, 
is the ratio of the concentration of RNA to the total concentration of RNA and drug, or: Mole 
Fraction = [RNA] / ([RNA] + [drug]). In this case, the sum of [RNA] and [drug] was held 
constant at 7 µM. The intersection of the two linear portions of the Job plot yield the mole ratio 
corresponding to the approximate binding stoichiometry between drug and RNA. This analysis 
revealed a mole fraction corresponding to ≈ 3.0 molecules of drug associating with each 
molecule of the H-chain IRE RNA. To further confirm the participation of the UG pairs in 
anthracycline binding, we also constructed Job plots using the fluorescence quenching data of the 
mutants IREs. We obtained a binding stoichiometry of ≈ 2.0 molecules of drug associating with 






Figure 2.4. Job plot of the fluorescence decay of DOX being titrated with ferritin H-chain IRE 
RNA. The sum of [RNA] and [drug] was held constant at 7 µM in each experiment {Mole 
Fraction = {([RNA] + [drug]) / [RNA]}. Each point was obtained from an average of at least 




In an effort to partition the binding free energies of anthracyclines with the IRE RNAs 
into their nonelectrostatic and polyelectrolyte contributions, fluorescence quenching was 
monitored over a range of Na+ concentrations, and a Stern–Volmer plot for each was plotted 
(Figure 2.3d) (21). The quenching constant (KSV) was determined for each curve and was then 
used to calculate the standard Gibbs free energy (∆G°) using the equation: 
∆G° = - RT ln KSV 
Where R is the gas constant (1.987 cal/K/mol) and T is the temperature in Kelvin. The quenching 
constants estimated at 25, 28, 30 and 35°C are 6.2 x 105 M-1, 5.0 x 105 M-1, 4.6 x 105 M-1 and 3.8 
x 105 M-1, respectively. A subsequent plot of log KSV versus log [Na
+] yielded the salt 





for DOX and ferritin H-chain IRE) was used in the following equation to determine the 
polyelectrolyte contribution (∆GPE) at a given salt concentration (21, 41): 
∆GPE = (SK) RT ln [Na
+] 
To determine the nonelectrostatic contribution to binding energy, the nonelectrostatic 
contribution to the free energy change (∆Gt) was calculated according to the equation (25): 
∆Gt = ∆G° - ∆GPE 
The values obtained for the binding of DOX to H-chain IRE RNA (BPE buffer, 16mM Na+, 
25°C) are as follows: ∆G°= - 7.7 kcal mol-1, ∆GPE = - 2.0 kcal mol-1 and ∆Gt = - 5.7 kcal mol
-1. 
The error associated with these values is estimated to be ± 0.1 kcal mol-1 (21). A comparable 
value of ∆GPE has been reported for the binding of DOX to DNA under similar conditions (21). 
 
Drug–RNA footprinting 
RNase footprinting was performed in order to probe the binding site(s) of DOX and DAU 
on the RNA constructs. Of the several RNases investigated, RNase T1 was found to provide the 
cleanest and most useful cleavage pattern. RNase T1 cleaves single-stranded RNA at the 3`-end 
of guanylic residues and, as expected, it caused strong cleavage of the RNA at G7, G16 and G18, 
all residues predicted by RNAstructure to be within the single-stranded region of the IRE 
secondary structure (Figure 2.5a). The most striking observation from this autoradiograph is that 
T1 cleavage at G22/G23 and G26/27, the nucleotide positions corresponding to the two UG sites, 
displayed a drug concentration-dependent increase in band intensity (Figure 2.5a). While G16 
also showed some variation in band intensity, comparison of the quantitated G16 and G23 band 













Figure 2.5 (a) Autoradiograph of RNase T1 footprinting of γ-32P 5`-end-labeled ferritin H-chain 
IRE RNA (lanes 1–8) and H-chain U10C mutant(lanes 9–16). Lane: (1) H-chain RNA only; (2–
8) RNA, RNase T1 and 0, 1, 2.5, 5, 10, 15, 20 µM DOX, (9) H-chain U10C mutant RNA only; 
(10–16) RNA, RNaseT1 and 0, 1, 2.5, 5, 10, 15, 20 µM DOX. The G 23 band, indicated by the 
arrow, is absent for the mutant. (b) Quantitations of theG16 and G23 bands intensities of ferritin 
H-chain IRE RNA after RNase T1 footprinting in the presence of DOX. DOX concentration for 





We then used RNase T1 footprinting to follow the effects of the aforementioned mutations on 
cleavage at G23, the guanylic residue of one of the UG pairs (U10G23) that showed T1 cleavage 
enhancement in the presence of DOX. We chose to monitor G23 because it is the better resolved 
of the two G residues on the autoradiograph (Figure 2.5a). In a manner similar to the wildtype H-
chain IRE, the footprinting of the G23I mutant with DOX displayed a drug concentration 
dependent increase in band intensity at G23 (data not shown). Conversely, the footprint of the 
U10C-IRE, the mutant which replaced the top UG pair, lacks the band corresponding to G23 
when compared to that of the wildtype H-chain IRE (Figure 2.5a). Validation of the cleavage 









Anthracycline–DNA interactions are among the best characterized in the literature (20-
28). Despite their chemical similarity to DNA and direct role in gene expression, little is known 
about the extent to which RNA interactions with anthracyclines contribute to anthracyclines’ 
biological activities. In this article, we demonstrate that DOX and DAU directly interact with the 
IRE hairpins (Figure 2.1a and b) located in the 5`-UTR of ferritin H- and L-chains mRNAs. 
DOX and DAU caused a concentration-dependent shift in the melting profiles of the H- and L-
chains IREs (Figure 2.2 and Supplementary Figure S1). In most cases, we observed higher ∆Tms 
for DOX compared to DAU for all IRE RNAs studied under the same conditions (Table 2.1). 
Since the magnitude of ∆Tm is an indication of the affinity of a probe molecule for a nucleic acid 
target (42), the noted differences in the values of ∆Tms suggest that DOX binds tighter to these 
RNAs compared to DAU. The lower ∆Tms observed for DAU (Table 2.1, bottom half) is 
consistent with the literature report indicating that DAU binds to DNA between 1.5- to 4-fold 
less strongly than DOX (27). Furthermore, the only structural difference between the two drugs 
is the presence of a primary OH-group at C14 of DOX (Figure 2.1c); it is therefore possible that 
the OH-group at C14 is playing a role in the binding of anthracyclines to the RNAs, perhaps in a 
similar manner to its involvement in DNA binding and recognition (43). 
The drug induced changes in the melting profiles of the mutant IREs gave further 
evidence for the base sequence preference of the interactions between the anthracyclines and the 
IRE RNAs. While the asymmetric bulge in the H-chain IRE is somewhat tolerant of a base 
change, the replacement of either or both of the UG wobble pairs flanking the asymmetric bulge 
with a CG significantly impaired DOX and DAU binding (Table 2.1). These results point to the 





However, the UG base pair recognition by anthracyclines may be RNA sequence dependent. 
Preliminary evidence to that effect was seen in the melting profile of a C22U mutant TAR RNA. 
Relative to the wild-type TAR RNA, we observed almost no change in ∆Tm of the C22U mutant 
in the presence of 20 µM DOX. This result may suggest that the microenvironment of the UG 
pairs within the RNA sequence may play important role in anthracycline recognition (see 
Supplementary Figure S2, for the melting profiles of wild-type and C22U mutant TAR RNA). 
The ability of IRE RNAs to alter the spectral characteristics of anthracyclines gives 
further indication of an interaction of drug and RNA (Figure 2.3 a and b). We observed a 
quenching of the natural fluorescence of DOX and DAU with increasing RNA concentration 
(Figure 2.3b). The quenching of DOX fluorescence by DNA has been ascribed to its intercalation 
into DNA (23, 44). Thus, we attribute the extensive fluorescence quenching (>90% at a 2:1 ratio 
of DOX to H-chain IRE RNA) to the intercalation of one or more anthracycline molecules per 
RNA molecule (Figure 2.3b). A similar interpretation has recently been proposed to explain 
DOX fluorescence quenching by a SELEX generated DOX RNA aptamer (45). Additionally, the 
titration of a fixed concentration of DOX with increasing concentrations of the wild-type H-
chain IRE results in a hyprochromic effect accompanied by a shift of the absorption maximum 
(λmax) to a longer wavelength (bathochromic shift). The observed maximal absorbance decrease 
is ≈ 33.7% (Figure 2.3a). These results are indicative of changes in the drug’s environment and a 
perturbation of the DOX chromophore system upon binding to the IRE RNA, consistent with 
intercalative binding of DOX within the IRE RNA. Furthermore, the apparent Kd (Table 2.2) 
extracted from the fluorescence quenching data give an indirect clue about the affinity of DOX 





contribution of direct drug binding and that of electrostatic interaction for all IRE constructs, the 
magnitudes of the apparent Kd’s suggest strong association of the drug with the IREs. 
We performed RNase footprinting experiments to gain more insight into the binding 
site(s) of DOX and DAU on the ferritin H-chain IRE and a series of mutant RNAs (46, 47). 
Results from the drug–RNA footprinting experiments show that the T1 cleavage at two sites, 
G22/G23 and G26/27, is enhanced upon addition of DOX (Figure 2.5a). Chaires et al. (47) have 
attributed an analogous enhancement in nuclease cleavage of DNA, in the presence of DAU, to 
the perturbation of DNA structure in the immediate vicinity of a DAU intercalation site. If this 
explanation holds for RNA, our results suggest the existence of at least two main drug binding 
sites at or near the two UG wobble base pairs of the ferritin H-chain IRE (Figure 2.5). Interaction 
of anthracycline molecules at both of these proposed binding sites would not violate the nearest 
neighbor exclusion rule when applied to anthracycline–nucleic acid binding (23). 
Wobble pairs, especially GU or UG, are ubiquitous building blocks of higher order RNA 
structures. Compared to regular Watson–Crick base pairs, wobble pairs differ in both the array of 
functional groups displayed in the helical grooves and the orientation of the bases with respect to 
the phosphodiester backbone. The consequence of this is that a wobble pair causes weakening of 
the helix and local distortions which significantly increase the electronegative environment at or 
near the mismatch pair (48, 49). The two UG pairs in the ferritin H-chain IRE could each provide 
an electronegative environment for nestling the electropositive DOX. In fact, the wobble pair has 
been shown to be a commonly conserved ligand binding site (48). To further probe this 
observation, we extensively studied the effects of mutation of the two UG pairs and bulge C on 
the binding affinity of DOX for the IRE RNA. Results from these experiments show that all 





in the wild-type RNA. This suggests that these mutants are able to induce the structural changes 
necessary for DOX binding within the vicinity of U10-G23. More importantly, however, the 
G23I mutant sheds light on the specifics of the UG pair recognition by DOX. The G23I mutation 
results in the deletion of the guanosine N2 exocyclic amine, a very distinct functional group 
displayed in the minor groove of a wobble that often serves as a specific receptor recognition 
signal. The fact that the G23I-IRE mutant also displayed increase in Tm and enhancement of T1 
cleavage at G23 in the presence of DOX suggest the G23 amine may not be essential for DOX 
recognition by the ferritin H-chain IRE (see Supplementary Material for the UV melting profiles 
for construct G23I, Supplementary Figure S5). An alternative mechanism of ligand recognition 
of a wobble pair is through its unique conformational features. This may well be exploited by 
DOX in its interaction with the H-chain IRE. This inference is supported by two key 
observations. First, the magnitudes of the observed ∆Tms for the G23I-IRE mutant are slightly 
higher than that of the wild-type in the presence of either DOX or DAU at all concentration 
studied (Table 2.1). These data suggest that the substitution of G23 for I may have resulted in 
slightly increased RNA ligand-binding affinity. Previous literature observation indicates that an 
IU base pair is slightly less stable than a GU pair (49). The subtle duplex instability as a result of 
the G23I mutation may enhance the structural changes essential for ligand binding, thereby 
resulting in increased interaction of ligand with the RNA. Second, the G23 band in the U10C, a 
mutant IRE in which the G23-U10 is substituted by a GC base pair, is protected from T1 
cleavage (Figure 2.5). Based on the increased GC content, one will expect this mutation to 
increase the binding affinity of DOX for the 5-base paired segment of the IRE. The protection of 
G23 from T1 digestion may be due to diminished or lack of DOX binding, thereby preventing 





DOX binding persists but is not accompanied by a conformational change that is sensitive to T1 
cleavage. 
The Stern–Volmer analysis of the drug fluorescence quenching data supports a static 
mechanism for the quenching of the DOX fluorescence by the H-chain IRE RNA (Figure 2.3c 
and d). The static quenching could occur through the formation of a complex, stabilized mainly 
by hydrophobic interactions, between DOX (fluorophore) and RNA (quencher) (37, 38). This 
complex could result from the intercalation of DOX into the IRE bases as suggested by the 
aforementioned evidence. In addition, the Stern–Volmer analysis allows an estimation of the 
equilibrium constant for the formation of the DOX-H-chain IRE RNA complex. Applying the 
polyelectrolyte theory (21, 41), these equilibrium constants enable the dissection of the RNA 
binding free energies of anthracyclines into their nonelectrostatic and polyelectrolyte 
contributions. The calculated value of ∆GPE is very similar to that reported for the binding of 
DOX to DNA under similar conditions (21). This result suggests a similar polyelectrolyte 
contribution to the overall ∆G of binding of DOX to DNA and RNA. A Job plot of the 
fluorescence quenching of DOX with wildtype IRE RNA gives a drug to RNA binding ratio of ≈ 
3.0:1 (Figure 2.4). A similar plot of the U10C IRE, a mutant in which one of the proposed 
binding sites has been replaced with a GC pair, resulted in a drug to RNA stoichiometry of ≈ 
2.0:1 (Supplementary Figure S3). This result is consistent with our original inference on the 
participation of U10-G23 wobble pair in DOX binding to the IRE. However, the drug to RNA 
stoichiometry remained ≈ 2.0:1 when both UG pairs are replaced (Supplementary Figure S3). 
The lack of further change in the drug to RNA ratio upon the replacement of the proposed 
second DOX binding site may be due to the fact that the second mutation did not completely 





sites, the nonelectrostatic binding energy, ∆Gt, was found to account for only 74% of the total 
observed change in ∆G upon DOX binding to IRE RNA. Taken together, these data suggest that 
in addition to the intercalation of two anthracycline molecules at the UG sites, there is at least 
one additional site of interaction, most likely electrostatic in nature, on the IRE RNA. 
The crystal structure of IRP1 bound to frog ferritin IRE has recently been solved (50). 
The structure reveals almost twice the number of specific interactions found in most protein–
RNA associations. Despite the level of interaction, single mutations to just a few of the residues 
involved have been shown to greatly diminish the IRE/IRP interaction (35, 51, 52). This high 
degree of structural and sequence selectivity reveals the seemingly robust interaction to be in fact 
very sensitive to minute disturbances. The binding of anthracycline molecules to the IRE 
structure could cause changes to the tertiary structure of the IRE RNA that could diminish the 
affinity of IRP for the IRE. This may cause an aberration in the intracellular regulation of the 
translation of mRNAs harboring these IREs. Supporting this hypothesis is a recent observation 
from the Thorp group on up-regulation of the cellular expression of ferritin upon exposure to 
yohimbine, a small molecule that binds to the ferritin IRE (53). Additionally, Butcher et al have 
recently described the binding of anthracyclines to an HIV-1 frameshift site RNA hairpin similar 
not only in structure to the IREs discussed here, but also in the Kd and ∆Tm values reported for 
the interaction (54). 
The biochemical evidence presented in this study suggests that anthracyclines form 
strong and specific interactions with IRE RNAs. Furthermore, it sheds light on some of the 
structural requirements for this interaction. Although anthracyclines such as DOX and DAU 
have been reported to show a requirement for GC sequences in DNA binding (47,55), we have 





preference for UG pairs. The prevalence of wobble base pairs in higher order RNA structures 
(48) suggests that this non-canonical pair, when structurally available, could serve as a 
ubiquitous recognition site for the binding of anthracyclines to other RNAs as well. Further 
studies are necessary to better understand the possible biological significance of the 
anthracycline-IRE interaction. Part of our ongoing effort is to probe the effects of DOX and 
DAU on IRE-IRP complex formation both in vitro and in vivo. 
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CHAPTER 3: PREFERENTIAL BINDING OF ANTHRACYCLINES TO 
DNA MISMATCH BASE PAIRS 
 
3.1 Known DNA/Anthracycline Interactions 
 
Anthracyclines are powerful antineoplastic agents that are widely used for the treatment 
of leukemia, lymphoma, solid-tumors and Hodgkin’s disease (1).  The general structure of 
anthracyclines consists of two dissimilar moieties: a planar hydrophobic tetracyclic (aglycone) 
ring and a hydrophilic, basic sugar (glycone) moiety attached to the tetracyclic ring through a 
glycosidic linkage (Figure 3.1a). The aglycone moiety intercalates between adjacent base pairs of 
DNA while the amino sugar ring lies in the minor groove of the B-DNA double helix. 
Anthracycline-DNA interactions are among the best characterized in the literature (2-27). 
Several X-ray diffraction and NMR structural analyses have provided valuable information 
regarding the binding interactions of anthracyclines with DNA (2-10). Additionally, extensive 
thermodynamic, kinetic, footprinting and computational studies have furnished detailed evidence 
on the molecular basis of the interaction of these compounds with certain DNA sequences (11-
21) Despite the extensive clinical utilization and successes achieved in characterizing 
anthracycline-DNA interactions, the exact mechanism of the anticancer activities of 
anthracyclines is still a subject of debate in the literature. Among the proposed mechanisms are 
topoisomerase II (topo II) inhibition via intercalating DNA, leading to inhibition of RNA and 
DNA synthesis, generation of pro-apoptotic free radicals and reactive oxygen species, inhibition 
of DNA strand separation (helicase activity) and direct membrane effects (28). Of these, the 
inhibition of intracellular topo II activity is still considered the primary mechanism of anticancer 
activity of anthracyclines because most other modes of action were demonstrated at 
concentrations well above the peak plasma concentration in patients undergoing anthracycline 







Figure 3.1 (a) Wild type (HWT) DNA hairpin structure (stars denote GT mutation sites), (b) X = 
OH, doxorubicin; X = H, daunomycin. 
 
 
It has been observed that loss of the human mismatch repair (MMR) pathway confers 
resistance to structurally unrelated anthracyclines including doxorubicin (DOX) (30, 31). In an 
effort to unravel the connection between anthracyclines and MMR-dependent drug resistance, 
Larson and Drummond demonstrated that anthracyclines including DOX, DAU, nogalamycin 
and actinomycin directly inhibit the human MMR pathway (32). The authors suggested that drug 
intercalation proximal to a mismatch may disrupt structural features essential for the recognition 
of the base pair mismatch. And in tune with the futile repair model, repeated and failed attempts 
to remove DNA lesions by the mismatch repair protein, upon base mismatch binding by 
anthracyclines, could contribute to observed anthracycline cytotoxicity (33, 34). However, this 
elegant work could not be used to conclusively define the exact molecular mechanism by which 





There exists very little support for base mismatch binding by anthracyclines. First, the 
mismatch-recognition domain of the MMR protein contacts DNA on the minor groove side (35, 
36). It is conceivable that the minor groove positioning of the glycone moiety could act as a 
steric impedance to the MMR protein binding to the base mispair. Supporting this steric 
impedance model is the observation that ethidium bromide, a DNA intercalator with a smaller 
minor groove binding moiety, inhibits MMR by about ten orders of magnitude less than DOX 
(32). Second, recent results from our lab suggest that anthracyclines preferentially bind to the 
GU wobble pair in ferritin iron-responsive element RNAs (37), thus it is quite possible that they 
may have a similar DNA base mismatch preference.  
To probe the possibility of preferential anthracycline binding at or near DNA 
mismatches, we have designed three hairpins containing canonical base pairs (wild type) or 
single and double GT mismatch mutations (Figure 3.1b).  We characterized the association of 
these hairpins with DOX and DAU, two clinically useful anthracyclines, using UV-melting, 
circular dichroism (CD), fluorescence quenching, and electrospray ionization mass spectrometry 
(ESI-MS) techniques. The results from these experiments revealed that DOX and DAU have 
binding preferences for the hairpins containing GT mismatches. An understanding of the binding 
preferences of anthracycline drugs will not only reveal the specifics of their induced MMR 
pathway inhibition, but should also prove to be valuable in the rational design of novel, 
anthracycline based derivatives and facilitate a more detailed assessment of the preferred targets 






3.2) Biophysical Characterization of Anthracycline / Hairpin DNA Interaction 
 
Oligonucleotides 
 The 19mer DNA hairpin targets were designed in such a way as to introduce a GT 
mismatch at two unique spots without compromising the hairpin structure (Figure 3.1b).  A wild 
type construct with sequence 5’-GCCTCCAAATCTTGGAGGC-3’ (designated HWT), a single 
mutation derivative introducing a C6T mutation with sequence  
5’-GCCTCTAAATCTTGGAGGC-3’ (designated H6), and a double mutant incorporating both a 
C6T and C2T mutation with sequence 5’-GTCTCTAAATCTTGGAGGC-3’ (designated HD) 
were procured from the W.M Keck Facility at Yale University (New Haven, CT).  
 
UV-vis melting and Circular Dichroism  
UV melting experiments were performed in the absence of drug and in the presence of 
DOX and DAU at final drug concentrations of 5µM and 20µM.  DNA and drug complexes were 
formed by the addition of an aliquot of stock drug solution in DMSO to a volume of DNA in 
BPE buffer (6mM Na2HPO4, 2 mM Na2H2PO4, 1mM EDTA, pH 7.1). The mixture was allowed 
to equilibrate for at least 20 minutes at 4 ºC to ensure complete association. The drug stock was 
prepared so that upon reaching the desired concentration of drug, the amount of DMSO in the 
sample was no more than 1% (v/v). Melting studies were performed over a temperature range of 
25-90 ºC, using a melting rate of 1 ºC/min data were collected every half degree. To form 
hairpins, constructs were heated at 99 ºC for one minute, then slowly cooled (1 ºC /min) to 10 ºC 





260nm, the temperature was controlled with a Quantum Northwest TC 125 temperature control 
unit, drug concentration varied between 5 and 20 µM, and the concentration of DNA was held 
constant at 2.5µM.  The Tm was taken as the midpoint of the melting transition as determined by 
the maxima of first derivative plots. All Tms were reproducible to within ± 1ºC.  The Tm of DNA 
in the absence of drug did not vary with increase in DNA concentration (Data not shown). 
CD spectra were acquired on a JASCO J-810 CD spectropolarimeter at 25ºC and were 
baseline corrected by subtracting a buffer only spectrum.  Samples were prepared in an identical 
fashion to those for UV-vis experiments.  Each presented spectrum is the average of three 
individual scans. 
 
Fluorescence Quenching Experiments 
Quenching of a drug’s fluorescence upon binding to DNA was monitored in titrations of 
a constant concentration of drug (7µM) with DNA of increasing concentration (0.1-20µM).  
Quenching experiments were performed in a 96 well black microplate following the protocol 
described by Hergenrother et al. (39).  Fluorescence emission at 556nm was recorded on a 
Molecular Devices SpectraMAX Gemini microplate reader after excitation at 480nm. All 
experiments were repeated at least four times. The data collected in the fluorescence quenching 
titrations were fit to a second order decay curve utilizing TableCurve 2D v5.01, equation 8107 








Where b is the apparent dissociation constant, x is the DNA concentration, y is the relative 





A stock solution of 4M NaCl in BPE buffer was diluted with BPE to achieve the various salt 
concentrations listed in the paper. 
 
Mass Spectrometry   
Drugs were dissolved in DMSO in stock solutions from 100 µM to 10 mM.  The hairpins 
were annealed in BPE buffer by cooling the samples overnight from 90oC to room temperature.  
Annealed samples were stored at -20 °C.  Each annealed hairpin (10 µM) was incubated with the 
desired concentration of the appropriate ligand for 20 minutes at 4 °C to allow for equilibration, 
and then 50 mM ammonium acetate was added prior to ESI-MS analysis to assist with desalting.  
ESI-MS was performed on a Thermo Scientific (San Jose, CA) LTQ-XL linear ion trap mass 
spectrometer.  The source conditions were optimized to minimize disruption of the hairpin/ligand 
complexes by maintaining the capillary temperature at 90oC and source voltage at 3.5 kV.  The 
tube lens voltage was set to -150 V, and all analyses were performed in the negative mode.  The 
extent of DNA binding is expressed as a “relative binding percentage”. For the calculation of 
relative binding percentages, peak areas were determined using Origin 7.0, and the peak areas of 
all hairpin/ligand complexes were summed and divided by the summed peak areas of all DNA 
species as shown in the equation below: 
 
Where PAHP is the peak area of the free hairpin and PAHP/Ln are the peak areas of the complexes 
containing each hairpin bound to n ligands.  Higher values of the relative binding percentages 








UV-vis melting and Circular Dichroism  
 The change in nucleic acid Tm after ligand binding (∆Tm = Tm (DNA + ligand) - Tm 
(DNA)) is an indication of the affinity of the ligand for the nucleic acid. When comparing wild 
type to mutant DNA ∆∆Tm (∆∆Tm = ∆Tm (mutant) - ∆Tm (wild type)), is an indicator of the 
contribution of the mutation to the affinity of the drug for the target DNA (40). As an initial 
assessment of binding affinity, DNA targets were melted in the presence and absence of 5µM 
and 20µM either DOX or DAU. The resultant Tm and calculated ∆Tm and ∆∆Tm values are 
presented in Table 3.1.  The wild type construct, HWT, produced a maximal shift in melting 
temperature of 15 °C in the presence of 20µM DOX. In comparison the H6 construct containing 
a single GT mismatch yielded a 21 °C increase in melting temperature under the same 
conditions. This represents an increase of 6 °C (∆∆Tm ) when compared to HWT. More notably 
HD in the presence of 20µM DOX showed a ∆∆Tm value of 18 °C. A similar concentration 
dependent trend was seen in the interaction of DAU with the DNA hairpins. In the presence of 





Table 3.1 Average Tm values (°C) and ∆G values (kcal mol









The CD spectra of 2.5µM HWT, H6 and HD in the absence and presence of 20 µM DOX 
are presented in Figures 3.2a and 3.2b, respectively.  The HWT construct in the absence of drug 
(Figure 3.2a, solid) produces a CD signal with clear positive and negative peaks at about 280nm 
and 250nm respectively.  Similarly, construct HD in the absence of drug (Figure 3.2a, dashed) 
showed positive and negative CD signals, albeit with markedly less intensity than those of HWT.  
Hairpin H6 in the absence of drug (Figure2a, dotted) lacked the symmetry and intensity of the 
CD signal of HWT.  Upon addition of 20 µM DOX, all three constructs showed a dramatic 






Figure 3.2 (a) CD spectra of 2.5 µM HWT (solid), H6 (dotted), and HD (dashed) DNA 
constructs in the absence of drug. (b) CD spectra of 2.5 µM HWT (solid), H6 (dotted), and HD 






Fluorescence Quenching  
The conjugated ring system of anthracycline molecules makes them natural fluorophores 
and the binding of the molecule via intercalation leads to the quenching of this fluorescence (39).  
The natural fluorescence of DOX subsequent to excitation was monitored upon titration of 
increasing concentration of all three DNA constructs and the resulting data was used to compute 
thermodynamic parameters. The resultant decay curves in BPE were fitted and yielded apparent 
dissociation constants of 1.43 ± 0.077 µM, 1.20 ± 0.053 µM, and 1.22 ± 0.048 µM for HWT, H6 
and HD, respectively. It is important to note that this apparent KD is a total dissociation constant, 
and does not differentiate between the contribution of direct drug binding (e.g. intercalation) and 
the contribution of electrostatic interaction due to the charged nature of the anthracycline 
molecule. 
To partition the binding free energies of anthracyclines with the DNA hairpins into their 
non-electrostatic and polyelectrolyte contributions, fluorescence quenching was monitored over a 
range of Na+ concentrations, and a Stern-Volmer plot for each was plotted as described 
previously (18, 37).  Stern-Volmer plots for HWT and H6 in the presence of both DOX and 
DAU can be found in Figure 3.3. Binding energy analysis was not done for HD because its Tm in 
the absence of drug is near room temperature. The quenching constant (Ksv) was determined for 
each curve and was then used to calculate the standard Gibbs free energy (∆G°) using the 
equation: 
∆G° = -RT ln Ksv 
Where R is the gas constant (1.987 cal K-1 mol-1) and T is the temperature in Kelvin. The wild 
type construct yielded Ksv values of 1.5x10
6 M-1 and 1.7x106 M-1 in the presence of DOX and 
DAU, respectively. The single mutant construct, H6, yielded Ksv values of 2.1x10





2.3x106 M-1 in the presence of DOX and DAU, respectively. A subsequent plot of log Ksv vs. log 
[Na+] yielded the salt dependence of the binding constant defined by the slope (SK) of such 
plots. The SK value was used in the following equation to determine the polyelectrolyte 
contribution (∆Gpe) at a given salt concentration (18): 
∆Gpe = (SK) RT ln [Na
+] 
To determine the non-electrostatic contribution to binding energy, the thermodynamic free 
energy change (∆Gt) was calculated according to the equation (18): 
∆Gt = ∆G° - ∆Gpe 
The ∆G°, ∆Gt and ∆∆Gt values obtained for the binding of DOX and DAU to HWT and H6 
(BPE buffer, 25°C, 16mM Na+) can be found in Table 1. We observed that the free energies 
change associated with drug binding to the mutant hairpin are lower (i.e. stronger affinities) than 









Figure 3.3 Stern-Volmer plots of 7 µM drug in the presence of DNA at the following Na+ 
concentrations: 16 mM (diamond), 46 mM (square), 116 mM (triangle), 216 mM (x), and 516 





 Electrospray ionization mass spectrometry (ESI-MS) was utilized to monitor the binding 
of drugs to all three DNA hairpin targets at various drug-DNA ratios. Hairpin/ligand complexes 
were abundant and easily identified in the resulting ESI-mass spectra.  As an example, Figure 3.4 
shows an ESI mass spectrum of hairpin HWT in the presence of 5 µM DOX (i.e. a 2:1 hairpin: 
ligand concentration ratio).  Complexes containing up to two DOX ligands bound to the hairpin 





salt adduction than are normally observed by ESI-MS due to the presence of the BPE buffer.  
The relative binding affinities of the ligands to each hairpin were calculated according to 
Equation 1 based on integration of peak areas of the various complexes and unbound hairpin in 
the ESI mass spectra for each incubate.  The results of the ESI-MS analyses over a range of 
ligand concentrations (and a constant hairpin concentration of 10 µM) until virtually saturated at 
20 µM ligand, are summarized in Figure 3.5.  As expected, the relative binding percentages 
increase with increasing ligand concentration.  
 







Figure 3.5 Relative binding percentages for the three hairpins HWT, H6, and HD with DOX at 







The specific binding of anthracyclines to Watson-Crick DNA base pairs is well 
understood (2-27). However the exact mechanisms of anthracycline chemotherapeutic and 
cytotoxic effects are still not agreed upon in the literature. Furthermore, it remains unclear 
exactly how anthracyclines induce an inhibition of the human MMR pathway.  Previous work by 
our group (37) provided a unique perspective from which to address these questions by 
investigating a possible DNA mismatch base pair preference of the anthracycline class of drugs. 
The affinity of the anthracycline molecule to bind at or near a mismatch base pair, such as the 
GT wobble pair, has not previously been evaluated to the best of our knowledge. The GT base 
pair imparts a unique geometry to the phosphodiester backbone of helical DNA (41) that may 
make it more accessible to a small molecule intercalator.  The presence of a GT wobble pair has 
been shown to be an absolute necessity in some molecular recognition events (42). 
  In this article we provide evidence suggesting that DOX and DAU, two representative 
examples of clinically useful anthracyclines, exhibit greater binding affinities for DNA hairpins 
containing GT mismatches compared to the WT hairpin.  The first evidence of this specificity is 
illustrated by the large positive ∆∆Tm values observed when comparing construct HWT to H6 
and HD. An increase in melting temperature of 4 degrees or more is considered an indication of 
the preference of a ligand for a target (43). The ∆∆Tm values in the presence of 20 µM DOX and 
DAU for H6 of 6 °C and 7°C respectively and for HD of 19 °C and 17 °C, respectively (Table 
3.1). The positive values of ∆∆Tm provide preliminary evidence for a strong specificity of 
anthracyclines for GT mismatch sites. It is important to note that the design of the double 
mismatch HD construct would allow binding of two DOX molecules at or near the mutation sites 





binding affinity is the drug binding free energy difference between the wild-type and mutant 
hairpins (∆∆Gt) (18). As shown in Table 1, introduction of a single GT base mismatch favored 
(negative ∆∆Gt) DOX and DAU binding to the mutant hairpin H6 by 0.2 and 0.3 kcal mol
-1, 
respectively. Although the magnitude of ∆∆Gt is small and we could not distinguish between two 
drugs, the data nevertheless is in agreement with the observed positive ∆∆Tm values. Together, 
these data give a clear indication of the preference of the drug molecule for the introduced 
mutation (18). Additionally, apparent dissociation constants for all three constructs in the very 
low micromolar range suggest a strong interaction between anthracycline and DNA.  
Circular dichroism has been used to characterize anthracyclines and the binding of 
anthracyclines to DNA targets (45-49).  Changes in the CD spectrum of an oligo in the presence 
and absence of drug, or in comparing wild type to mutant constructs under similar conditions, 
can be used to determine if there are changes in the oligos secondary structure. Changes in this 
structure could point to changes in the binding environment of the ligand. Thus, comparison of 
CD spectra (Figure 3.2a and 3.2b) allows a glimpse at changes in the structure of the DNA 
hairpins upon DOX binding. As expected, the CD signal of HWT in the absence of drug (Figure 
3.2a) is characteristic of a B-form DNA helix (47, 48).  Also as expected the mutant constructs 
H6 and HD do not yield the symmetry or intensity of HWT’s CD signal as their structures are 
likely altered by the presence of the GT mismatches. This difference in the mutant constructs’ 
CD spectra could indicate a unique small molecule binding environment when compared to the 
HWT hairpin. The marked changes in the CD spectra of all three constructs upon incubation with 
the drugs (Figure 3.2b) are further evidence of ligand binding and subsequent induced changes in 
structure.  The enhanced binding of drug to the mutant DNA hairpins may be related to not only 





subsequent to the binding of one or more drug molecules (50). The structural changes to the 
double stranded DNA helix are expected to be evident in the mutant hairpins, relative to the 
wild-type, due to ease of unwinding at or near the base mismatch sites. It is these changes in 
structure that have been proposed to be related to the observed MMR pathway inhibition by 
anthracyclines (32). 
Electrospray ionization (ESI) allows the transfer of non-covalent complexes from 
solution to the gas-phase, thus facilitating the analysis of many types of biological complexes by 
mass spectrometry.  This permits the study of duplex (51-53), triplex (54) and quadruplex (54-
60) DNA structures, as well as the determination of binding selectivities, stoichiometries, and 
binding affinities of metal-mediated DNA complexes (61, 62), DNA/protein complexes (63, 64), 
and other DNA/ligand complexes (61, 65-70). Perhaps the most compelling evidence for the 
possible drug GT mismatch preference comes from the ESI-MS results (Figure 3.4).  First, the 
detection of DNA-drug complexes suggests that these complexes are sufficiently stable even in 
the gas phase. More importantly however, comparison of the relative binding percentages for 
DOX and DAU concentration ranging from 1 to 10 µM indicate that they exhibit greater binding 
affinities for the mismatched hairpins H6 and HD compared to the HWT hairpin (Figure 3.5).  
The differences were significant to a 95% confidence interval in most cases.  For the solutions 
containing the greater ligand concentrations (20 and 50 µM), the relative binding percentages 
were similar for all three hairpins (Figure 3.5), suggesting a possible drug saturation at higher 
ligand concentrations. 
Collectively, the evidence presented in this study suggests a strong and specific 
preference of the anthracycline drugs for GT mismatch base pairs.  This result agrees with our 





While it cannot be said with certainty that the preferential interaction of drug at mismatch sites, 
and the resulting change in binding environment, plays a role in anthracycline induced MMR 
pathway inhibition, it does corroborate the theory proposed by Larson and Drummond (32). 
Further studies involving anthracycline derivatives, namely derivatives with changes made to the 
glycone moiety of the molecule, will be needed to assess the exact structural basis for MMR 
inhibition resultant to anthracycline exposure. A detailed understanding of this interaction could 
prove to help elucidate the preferred nucleic acid targets of anthracycline drugs. In turn this will 
facilitate the future design of unique, anthracycline based drugs to be employed not only as 
structural probes, but also as novel therapeutic agents with differential pharmacokinetic 
parameters.  Toward this end, one of the ongoing efforts in our lab is the design, synthesis, and 
characterization of novel anthracycline derivatives. 
 
*This work was done in collaboration with Sarah E. Pierce and Dr. Jennifer S. Brodbelt at 
The University of Texas at Austin. With the exception of the ESI-MS results, Joshua 
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CHAPTER 4: EXPLORING THE RIBOSOME WITH NOVEL 
MACROLIDE-PEPTIDE CONJUGATES 
 
4.1 Architecture of the Ribosomal Exit Tunnel 
 
 The ribosome is one the most complex molecular machines found in nature.  The peptide 
producing mechanisms of the ribosome are so finely orchestrated and perfectly tuned that they 
are one of the more conserved features in the tree of life. Once described simply as a small 
particle containing peptides and nucleic acids, the ribosome is far better understood today, but 
still presents some mystery. While crystal structures have allowed the identity of all ribosomal 
components to be elucidated, the exact role that each of the structures play during translation 
remains unclear (1-4). The ribosomal exit tunnel is an example of such a component that has yet 
to be fully characterized. The 80 Å long, 20 Å wide, rRNA lined exit tunnel serves as the route 
of egress for nascent peptides to move away from the petidyl transferase center (PTC) towards 
the exterior surface of the ribosome (5,6). The unobstructed pathway from the PTC along the exit 
tunnel and out of the ribosome was initially believed to be Teflon-like in nature and to have little 
impact on the escape of the nascent chain. However, it has been shown that specific peptide 
sequences allow the nascent chain to interact with the walls of the exit tunnel, thereby 
influencing translation (7). While specific sequences have been identified to stall translation, it is 
still not fully understood why the majority of peptides pass through the tunnel unhindered while 





4.2 Peptolide Design and Synthesis 
 In an attempt to interrogate the exact nature of the exit tunnel, we describe here the 
rational design, synthesis and characterization of a novel class of peptide-ketolide (“peptolide”) 
molecular probes.  Ketolides are a class of antibiotic small molecules, largely known as 
macrolides, which interfere with the prokaryotic ribosome by physically blocking a portion of 
the exit tunnel near the PTC (Figure 4.1) (10). As an inspiration in the design of the peptolide 
probes we looked to the ketolide telithromycin (TEL). Unique to TEL is a flexible alkyl-aryl 
moiety (Figure 4.2a). This flexible arm of the TEL molecule has been shown via crystallographic 
studies to adopt several different binding motifs (11).  The arm can either extend back up the exit 
tunnel towards the PTC, follow the expected path of a nascent chain down the exit tunnel away 
from the PTC, or extend to the side as observed in the large ribosome subunit (50S) from 
archaeal Haloarcula marismortui (H50S), bacterial Deinococcus radiodurans (D50S), and E. 
coli, respectively (Figure 4.2b).  
 
Figure 4.1 Erythromycin bound to the macrolide binding pocket adjacent to both the PTC and 






Figure 4.2 A) Structure of the macrolide class drug, telithromycin (TEL). B) Crystal structure of 
TEL bound to the large ribosomal subunit of H50S (gold, extending toward PTC), D50S (cyan, 
extending toward exit tunnel), and E. coli (pink) Figure adapted from (11). 
 
 
It is evident in all three crystal structures that the bound TEL molecule is stabilized by 
similar stacking interactions between the aryl moiety of the arm and pyrimidine bases of the 
ribosomal rRNA. As long as this crucial energy minimizing interaction remains intact, it is 
feasible that the arm could be modified beyond the aryl group and allow new ligands to be added 
while preserving the antibiotic binding mode. By utilizing Cu (I) catalyzed Huigsen 
cycloaddition (click chemistry) as the crucial fragment joining reaction, we can replace the 
imidazole ring of the aryl group with the structural similar triazole linkage (Figure 4.3). Thus, the 
dynamic nature of TEL’s aryl alkyl arm could provide an optimal, flexible linker by which to 
attach a variety of peptide moieties to the macrolide head group.  By employing the macrolide as 
an anchor, any attached peptide sequence would be presented to the exit tunnel and its binding 
mode and affinity could be analyzed to glean insight as to the nature of interaction with the local 

































We rationally designed and successfully synthesized a series of peptolide probes via an 
11 step synthetic route starting with clarithromycin (Figure 4.4) (Synthesis performed by Derek 
Benicewicz). We created an azide-ketolide intermediate that could be used as the universal head 
group for all compounds created. Thus a peptide of any design, so long as it was functionalized 
with an alkyne, could be attached to create a complete peptolide. We produced four unique 
structural motifs by varying the peptide tail in amino acid composition, size and direction of 
attachment (Figure 4.4).   Additionally, each of the four unique peptolide motifs were further 
differentiated by two linker lengths, 3 carbon and 4 carbon, or n=0 and n=1 respectively in 
Figure 4.4,  between the ketolide and peptide, giving us a total of eight structurally differentiated 
peptolide probes.  These probes were named by their linker length (3C or 4C) as well as by their 







                                                  
                                                               



























































































































































































4.3 In vitro Cell Extract Inhibition Assays 
As a first indication of the effects of our newly created peptolide probes on the fidelity of 
ribosomal function, we subjected them to a pair of distinct cell free transcription/translation 
assay kits and determined their inhibitory IC50 values. The first of the assays, representing a 
prokaryotic system, is based on a whole cell extract of E. coli (E. coli T7 S30 Extract System for 
Circular DNA, Promega). The second assay is a eukaryotic system comprised of rabbit 
reticulocyte whole cell extract (Rabbit Reticulocyte Lysate System, Nuclease Treated, Promega). 
Assays were performed in accordance with the suggested manufacturer’s instructions (Promega) 
(12, 13). Both assays utilize a luciferase based reporter whereby protein expression, or the 
inhibition thereof, is monitored via the inherent luminescence of the encoded luciferase protein 
product. In the case of the prokaryotic system, transcription and translation occur simultaneously 
due to the lack of a defined nucleus. Thus a DNA template of the luciferase product is introduced 
to the reaction mixture for subsequent and simultaneous transcription and translation.  In 
contrast, in the eukaryotic assay the production of luciferase is solely dependent on translation as 
only an RNA template of the luciferase product is present in the reaction mixture. Also tested for 






Table 4.1 IC50 values of in vitro, cell free assays performed on peptolide compounds.                                      
 









4.4 Chemical Footprinting of E. coli 23S rRNA 
 Chemical footprinting of the E. coli 23S rRNA was performed with dimethyl sulfate 
(DMS) and 1-cyclohexyl-(2-morpholinoethyl)carbodiimide metho-p-toluene sulfonate (CMCT) 
according to the following protocol (14): 
Peptolide Binding 
All peptolides and the azido-macrolide precursor were incubated at a final concentration 
of 150 µM with 100 pmol E. coli 70S ribosome (New England Biolabs), whereas clarithromycin 
was incubated at a concentration of 50 µM. Binding was performed in binding buffer (10 mM 
HEPES, 10 mM MgCl2, 60mM NH4Cl) at 37°C for 30 minutes (15). 
DMS Chemical modification 
DMS chemical modification was performed on intact 70S E. coli ribosomes in the 
absence and presence of bound drug. Approximately 50 µg of intact ribosome, or ribosome-
peptolide complex, in 25 µM DMS buffer (80 mM K-HEPES, 10 mM MgCl2, 100 mM NH4Cl) 
was alliquoted and to this was added 1 µl DMS Stock (880 mM DMS in abs. EtOH) and the 
mixture was then incubated for 10 minutes at 37°C. The reaction was terminated by the addition 
of 12.5 µl of DMS stop buffer (1 M tris-HCl, 0.1 M EDTA, 1 M 2-mercaptoethanol, pH7.5). 
Ethanol precipitation was followed by RNA extraction: The RNA pellet was resuspended in 400 
µL extraction buffer [0.3 M NaOAc (pH 6.5), 0.5% SDS, 5 mM EDTA (pH 8.0)] at room 
temperature.  This was subsequently extracted three times via addition of 400 µL of acid phenol 
chloroform (pH 4.5, Invitrogen).  The final RNA fraction was ethanol precipitated and the pellet 









 CMCT chemical modification was performed on intact 70S E. coli ribosomes in the 
absence and presence of bound drug. Approximately 50 µg of intact ribosome, or ribosome-
peptolide complex, in 25 µM CMCT buffer (50 mM potassium borate pH 8.0, 10 mM MgCl2, 
100 mM NH4Cl) was alliquoted and to this was added 12.5 µl CMCT Stock (100 mM CMCT in 
CMCT buffer) and the mixture was then incubated for 10 minutes at 37°C. The reaction was 
terminated by the addition of 2.5 volumes of -20°C 95% EtOH. Subsequent ethanol precipitation 
was followed by RNA extraction as described above. 
Reverse Transcription 
A list of primer sequences was generously provided by Dr. Alexander Mankin. DNA 
primers were purchased from Keck Biotechnology (New Haven, CT).  An array of primers was 
initially purchase with the intent of covering as much of the 23S rRNA strand as possible. After 
footprinting analysis of all primers, the primer yielding the most useful data, named primer 2180, 
has the following sequence: 5`-GGGTGGTATTTCAAGGTCGG-3` . Primer 2180 is named as 
such because the 5` G of the primer anneals to position 2180 (E. coli numbering) of the 23S 
rRNA. Primer concentration was determined by UV-vis spectroscopy in 1 cm path length quartz 
cuvettes using molar extinction coefficients determined by OligoAnalyzer (IDT).  
A working primer stock (2.0 µM) in H2O was made fresh for each reaction.  A 
hybridization buffer (225 mM K-Hepes pH 7.0, 450 mM KCl) was used to bring primer 
concentration to 1.0 µM.  This primer mix (2 µL) was added to tubes containing RNA (0.8 
µmol).  Annealing proceeded by placing tubes in a water bath at 90oC for 1 min, and allowed to  
cool to room temperature.  While cooling, a master mix was prepared using 20 µL 5x First 





dNTP mix (110 µL 1mM d(T, G, C)TP, 6 µL 1 mM dATP, 664 µL H2O), and 1 µL each of 
RNasin Plus (Promega) and 100 mM dithiothreitol (DTT). 
Upon completion of annealing, samples were briefly centrifuged at room temperature.  
Each tube received 2 µL master mix and the sequencing tubes received the appropriate ddNTP (1 
µL, 9 µM).  Added last to each tube was 200U SuperScript II reverse transcripase (Invitrogen).  
Tubes were gently mixed and centrifuged before being placed in a heating block at 55oC for 30 
minutes.  Chase was initiated by addition of 1 µL dNTP (100 mM) to each tube and 1 µL 
appropriate ddNTP (402 mM) to sequencing tubes.  Tubes were placed back in the heating block 
at 55oC for 15 minutes.  The reaction was terminated by the addition of precipitation buffer (75 
µL, 95% ethanol, 0.3 M NaOAc pH 6.5, 4oC) and centrifuged for 90 min (13,200 rpm, 4oC).  The 
supernatant was removed and the pellets were dried and resuspended in 10 µL loading buffer 
(95% formamide, 10 mM EDTA, 0.1% xylene cyanol, 0.1% bromophenol blue, pH 11). 
Gel Protocol 
Samples were analyzed by running on a 5% polyacrylamide gel in a Sequi-Gen GT 
system (Bio Rad).  The gel and 1x TBE buffer (100 mM Tris, 90 mM Boric Acid, and 1 mM 
EDTA) were brought to temperature by pre-running at 55 W to 50oC.  Lanes were thoroughly 
flushed with buffer and loaded with 1 µL of sample each.  Migration occurred from 45 to 90 min 
at 55W and 50°C.  Gels were transferred to Whatman paper and were fixed in 20% EtOH for 20 
min.  They were then dried under vacuum for 90 min at 80oC.  Once dry, gels were exposed onto 
a phosphor screen (GE Health care) overnight.  Screens were scanned on a Typhoon Trio+ (GE 
Health care) and digital images were analyzed with Multi Gauge (FujiFilm). 
The footprinting of E. coli 23S rRNA with primer 2180 and DMS modification in the 
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Figure 4.5 Footprinting of 23S rRNA with primer 2180. Dideoxy sequencing lanes G,C,A and T 
followed by lanes: 1) unmodified  rRNA, 2) DMS modified 23S rRNA, 3-4) DMS modified 23S 
rRNA in presence of clarithromycin and azido-ketolide intermediate, respectively, Lanes 5-12) 
23S rRNA DMS modified in the presence of 3C NLS, 4C NLS, 3C rNLS, 4C rNLS, 3C PLI, 4C 
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Figure 4.6 Footprinting of 23S rRNA with primer 2180. Dideoxy sequencing lanes G,C,A and T 
followed by lanes: 1) unmodified  rRNA, 2) CMCT modified 23S rRNA, 3-4) CMCT modified 
23S rRNA in presence of clarithromycin and azido-ketolide intermediate, respectively, Lanes 5-
12) 23S rRNA CMCT modified in the presence of 3C NLS, 4C NLS, 3C rNLS, 4C rNLS, 3C 







As can be seen in Table 4.1, each of the peptolide probes retained some degree of 
prokaryotic translation inhibition.  This data serves as an initial confirmation that the structural 
changes introduced did not completely diminish the probes’ antibiotic properties. Several trends 
can also be seen in the prokaryotic IC50 values. Without exception the peptide tails alone did not 
cause inhibition, confirming that any inhibitory activity observed is from the conjugated 
peptolide probe. When comparing the NLS conjugate to the reverse, or rNLS conjugate, it can be 
seen that directionality of the peptide attachment does not seem to have much of an effect on the 
translation inhibition of the probe. However, the length of the linker does seem to play an 
important role in the inhibitory potential of each peptolide with the 4C molecules being more 
potent inhibitors in all cases except for rNLS.  
The most striking difference in inhibition is evident when comparing the amino acid 
composition of the peptides. The overall charge of the residues comprising the peptides 
decreases in positive charge in the order NLS & rNLS (+5), PLI (+3), and RGD (zwitterionic). 
The potency of inhibition also follows this trend with the NLS conjugates being the strongest 
inhibitors and RGD being the weakest. This can be rationalized by considering the environment 
present in the exit tunnel. Being lined with almost exclusively rRNA, having a negatively 
charged backbone, the exit tunnel certainly provides an inviting negatively charged cavity for an 
electro positive peptide such as NLS to selectively nestle.  This favorable charge interaction can 
also be used to explain the increase in potency seen when comparing the macrolide alone to the 
NLS peptolide . 
The rabbit reticulocyte assay was initially done as a control experiment to confirm the 





peptide alone, showed some degree of eukaryotic inhibition. The erythromycin macrolide is a 
prokaryotic selective inhibitor of translation showing no activity in the rabbit reticulocyte assay. 
The PLI peptide alone showed slight inhibition with an IC50 of 205µM. When conjugated with 
the optimal linker length of 4C the conjugate of the macrolide and PLI peptide showed 
significant inhibition of eukaryotic translation with an IC50 of 38µM.  
Footprinting of the 23S rRNA of E. coli was performed to further characterize the 
interaction of the peptolide probes with the ribosome. The modifying agents employed DMS and 
CMCT. DMS modifies the rRNA by methylating available adenosine and cytosine residues (16). 
Bases available to modification include those that are single stranded, base paired at the end of a 
helix, or adjacent to a GU wobble pair. Methylation occurs at the N1 of A and the N3 position of 
C. Similarly, CMCT modifies the N3 of U and N1 of G of any available bases (17). As the RT 
enzyme travels down the RNA creating a compliment DNA (cDNA) strand, it will stall at these 
sites of modification and yield truncated cDNA products. By modifying the rRNA in the absence 
and presence of the peptolide probes, any changes in availability of certain bases to DMS or 
CMCT modification can be used to indicate sites of drug interaction.   
 The footprinting gel in Figure 4.5 shows a clear peptolide footprint at residue A2058 of 
the E. coli 23S rRNA. Lane 1 is unmodified rRNA and lane 2 is DMS modified rRNA in the 
absence of probes. Any differences between lanes 1 and 2 highlight residues that are available 
for DMS modification. Similarly, any differences between lane 2 and lanes 3-12, lanes 
containing rRNA that is DMS modified after drug or probe binding, will highlight any sites that 
have changes in DMS availability.  The bold band at A2058 in lane 2, and its greatly reduced 
intensity in the presence of all peptolide lanes, is clear evidence of a drug binding footprint. This 





well-defined macrolide binding pocket of the ribosome as discussed in chapter 1 of this thesis.  
Thus, this footprinting results verifies that the binding target of the peptolide probes is indeed the 
same as the parent macrolide drug.  
 Another significant trend observed in Figure 4.5 can be seen in the A2058 band in the 
peptolide lanes. In almost all of the lanes the A2058 band is gone or barely visible. The 
exception to this is the darker A2058 band present in lane 11. This lane is the 23S rRNA DMS 
modified in the presence of the 3C RGD peptolide probe. The enhanced intensity of this band in 
copmparison to the other lanes is indicative of a decreased binding affinity of the 3C RGD 
peptolide for that footprinting site. The weaker the binding, the more accessible the residue is to 
DMS. Looking back to Table 4.1 it can be seen that the 3C RGD peptolide was in fact the worst 
performing probe with an IC50 value of 60 µM in the E. coli assay. This provides a direct 
correlation between our in vitro translation inhibition studies and our DMS footprinting results. 
 While the footprint observed in Figure 4.5 provided a verification of the macrolide 
portion of the probes finding themselves at home in the macrolide binding pocket, the CMCT 
footprint of Figure 4.6 reveals the residence of the peptide tail portion. Lanes 2-4 show a clear 
band corresponding to U1963. This residue is thus available to CMCT modification in the 
absence and presence of both clarithromycin and the azido-ketolide intermediate. In marked 
contrast, residue U1963 is totally protected from modification by CMCT in the presence of all 
peptolide probes as evidenced by the absence of this band in lanes 5-12 of Figure 4.6. Examining 
the crystal structure of a macrolide bound to the 50S subunit of the E. coli ribosome confirms 







Figure 4.6 Crystal structure of erythromycin (yellow) bound to the 50S subunit of E. coli. This 
image is a complete spacefill of the entire large ribosomal subunit. U1963 (white) lies on the 
surface of the 50S subunit, at the 30S interface, and is reachable by the peptolide tail through an 






 To conclude, we rationally designed, synthesized and validated the nucleic acid binding 
target of a novel class of macrolide-peptide conjugate probes known as peptolides. These 
peptolides are intended to bind in the exit tunnel of the ribosome and provide insight as to the 
nature of the exit tunnel environment. It was demonstrated that all peptolides created retained 
some degree of the antibacterial property inherent in the parent macrocyclic molecule. In vitro 
results showed that the size and direction of attachment of the peptide tails did not have much 
influence on the overall translation inhibition ability of the probes. Contrastingly, the overall 
charge of the peptide tail proved to have the greatest influence on inhibitory IC50 values with the 
most positively charged peptide, NLS, proving to be the most potent.  Additionally, DMS 
footprinting of the 23S rRNA of the E. coli ribosome showed that the peptolide probes retained 
the interaction mode of the parent molecule by binding to the macrolide binding pocket in the 
exit tunnel. The location of the peptide tails of the peptolides was also deduced via CMCT 
footprinting and showed a binding position in the direct vicinity of residue U1963.  
The unique peptide tail binding in the direct area of the PTC and subunit interface of the 
prokaryotic ribosome, coupled with potent translational inhibition in vitro could certainly make 
the peptolide family of probes a viable, novel antibiotic class of drugs. By almost doubling the 
size of the binding pocket, the novel peptolides compounds may be able to still bind to the 
ribosome despite mutations that typically lead to resistance. For example, the methylation of 
A2058 confers macrolide resistance to E. coli; by sampling an entirely new portion of the 
ribosome with its tail portion, a peptolide may still bind tightly even with the additional methyl 
group in the macrolide binding pocket. Furthermore, as a result of the observation of this thesis 
work that some peptolides also posses eukaryotic translation inhibition capabilities, they could 





plasmodium, leishmania, or tumor cells. Additionally, different head groups could be utilized in 
creating new peptolides; for example, an oxazolidinone antibiotic could be employed to sample a 
different binding area of the ribosome.  
*Some of the work presented in this chapter was done in collaboration with Arren 
Washington. Mr. Washington will continue the analysis of the peptolides presented here, and 
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CHAPTER 5: CHARACTERIZATION OF NOVEL TOPOISOMERASE II / 
HISTONE DEACETYLASE INHIBITOR CONJUGATES: NUCLEIC ACID 
BINDING PROPERIES 
 
Part of this work was published by William Guerrant, Vishal Patil, Joshua Canzoneri, and 
Adegboyega K. Oyelere in the Journal of Medicinal Chemistry2012 (55), 1465-1477. Sections 
5.1-5.7 represent a portion of said published manuscript, and are presented here unchanged. 
Sections 5.8and 5.9 present and discuss additional work done by Joshua Canzoneri and 





Strategies to ameliorate the flaws of current chemotherapeutic agents, while maintaining 
potent anticancer activity, are of particular interest.  Agents which can modulate multiple targets 
may have superior utility and fewer side effects than current single-target drugs.  To explore the 
prospect in cancer therapy of a bivalent agent that combines two complimentary chemo-active 
groups within a single molecular architecture; we have synthesized dual-acting histone 
deacetylase and topoisomerase II inhibitors.  These dual-acting agents are derived from 
suberoylanilide hydroxamic acid (SAHA) and anthracycline daunorubicin; prototypical histone 
deacetylase (HDAC) and topoisomerase II (Topo II) inhibitors respectively. We report herein 
that these agents present the signatures of inhibition of HDAC and Topo II in both cell-free and 
whole cell assays. Moreover, these agents potently inhibit the proliferation of representative 
cancer cell lines. Additionally, the ability of these novel compounds to bind to DNA and RNA 
hairpin targets was investigated, highlighting a preference for the compounds to ding to DNA but 








5.2 Rational Design of TopoII / HDACi Conjugates 
 
Several rational pharmacological strategies, including vaccination, gene therapy, 
immunotherapy, and new target identification and validation, have emerged for the treatment of 
metastatic diseases. Despite these progresses, chemotherapy remains the primary treatment of 
choice for most cancer cases. However, almost all chemotherapeutic agents suffer from severe 
toxicities and other undesirable side-effects. To address these problems, the cancer medicine of 
the future will incorporate, within a single molecule, elements that allow for simultaneous 
targeting of multiple cancer-fighting targets while maintaining lower side effects (1-3). This 
realization has continued to spawn immense efforts in the literature. Studies aimed at identifying 
multivalent ligands as promising pharmacological tools, that may be more efficacious for various 
human diseases than highly selective single-target drugs, are ongoing in several academic and 
pharmaceutical labs (4-7). A subset of these studies has revealed that balanced modulation of a 
small number of targets may have superior efficacy and fewer side effects than single-target 
treatments (1,7,8).  
Epigenetic control has become widely accepted as a mechanism for cell regulation (9-
11).  Specifically, histone deacetylase (HDAC) is a class of epigenetic enzymes that has 
generated much interest in cancer therapeutics literature.  HDACs are known to associate with 
many oncogenes and tumor suppressors, leading to altered expression patterns, and have 
consequently become attractive targets for small-molecule inhibition (12,13). Histone 
deacetylase inhibitors (HDACi) have been shown to cause growth arrest, differentiation, and 
apoptosis in tumor cells and in animal models by inducing histone hyperacetylation and p21waf1 





diverse range of proteins, many of which are attractive therapeutic targets themselves, including 
p53, E2F, tubulin, and Hsp90 (18-22). HDAC inhibition has been clinically validated as a 
therapeutic strategy for cancer treatment with the FDA approvals of suberoylanilide hydroxamic 
acid (SAHA) and romidepsin (FK-228) for treatment of cutaneous T cell lymphoma (23-25). 
However, a large number of the currently known HDACi have elicited only limited in vivo 
antitumor activities and have not progressed beyond preclinical characterizations (26-28). 
HDACi that modulate the functions of additional intracellular targets, other than the various 
HDAC isoforms, may be able to ameliorate many of the shortcomings of current inhibitors.  
Due to the presence of large hydrophobic patches at the HDAC surface rim it is 
conceivable that appropriate conjugation of the surface recognition group of a prototypical 
HDACi to other hydrophobic anti-tumor pharmacophores could furnish a new class of 
bifunctional agents (29,30).  To date, there exist a few examples of this subtype of bifunctional 
HDACi derived compounds (31-33). Expansion of the repertoire of such bifunctional compounds 
could lead to broad acting, therapeutically viable anti-cancer agents. 
An attractive starting point for a secondary target is the topoisomerase class of enzymes 
(Topo I and Topo II), which are validated targets for many small molecule inhibitors including 
clinically useful anthracyclines such as doxorubicin (DOX) and daunomycin (DAU) (Figure 
5.1); and camptothecins such as irinotecan and topotecan (34). Topo inhibitors elicit anticancer 
activities primarily by stabilizing the DNA-enzyme cleavable complex through intercalation 
between DNA base pairs.  However, DNA does not exist as a naked structure in the nucleus. It is 
non-covalently associated with histones to form the nucleosomes which make up chromatin 
subunits.  Agents, such as HDACi, that induce hyperacetylation of histone proteins complexed 





the anticancer activities of Topo inhibitors (35-36). Moreover, recent observations have shown 
that HDAC1, HDAC2 and Topo II co-localize in vivo as part of functionally coupled complexes 
(37-38). This evidence suggests simultaneous Topo and HDAC inhibition could be a viable 
alternative approach in cancer therapy.  
Anthracyclines are one of the most thoroughly studied classes of anticancer agents with 
copious structure activity relationship (SAR) data to aid the design and characterization of new 
anthracycline-containing compounds (39-44).   
 
Figure 5.1 Representative structures of anthracycline antibiotics. 
 
Specifically, N-benzylated anthracyclines, such as N-benzyl doxorubicin (AD-288) (Figure 5.1) 
(42), have enhanced Topo II inhibitory activities, reduced cardiotoxicity activity, and reduced 
susceptibility to the Pgp-mediated multidrug resistance (45-47). We postulated that introduction 
of the HDACi via N-benzylation of the DAU amino group would be compatible with Topo II 
inhibition and possibly engender the positive attributes of N-benzylated anthracyclines to the 
resulting conjugates.  In turn, the anthracycline moiety could serve two other purposes:  i) as a 
surface recognition cap group, allowing favorable orientation of hydroxamic acid within the zinc 
binding pocket of HDAC, and ii) as a delivery vehicle, since the transport of the anthracycline 
via proteasome could facilitate nuclear accumulation of HDACi (43). Based on the forgoing, we 





hydroxamate conjugates (Figure 2). The later conjugates were inspired by our previous studies 
which revealed that triazole moiety could be incorporated in lieu of amide bond as a surface 
recognition connecting group in prototypical HDACi (48). A total of 5 unique topoII / HDAC 
inhibitor conjugates were synthesized by Dr. Vishal Patil (Scheme 5.1 and Scheme 5.2). 
 





























































































5.3 In vitro HDAC Inhibition 
 
We first tested the HDAC inhibition activity of compounds 7 and 12a-d against crude 
HeLa cell nuclear extract HDACs using a cell free assay (Fluor de Lys) as previously described 
(48). Overall, these compounds showed inhibition activities against HeLa cell nuclear extract 
HDACs which are comparable to or exceed that of the standard SAHA (Table 5.1).  It is 
particularly interesting that 7 has identical anti-HDAC activity to SAHA.  This result suggests 
that the attachment of DAU does not impair the interaction between the HDACi component of 
the conjugate and the HDAC enzyme outer surface residues.  It is also conceivable that the 
conjugate may adopt a conformation whereby the anthracycline moiety can contribute positively 
to the interaction with the crucial active site or surface residues.  All triazole-linked conjugates 
potently inhibit HeLa cell nuclear extract HDACs with IC50 in the low to mid-nanomolar range.  
Among these conjugates, 12a is the least active, closely followed by 12d which is about 20-fold 
more potent.  Compounds 12b and 12c have the most potent anti-HDAC activity, with a slight 
preference for the six methylene-linked 12c.  Interestingly, the triazole-linked compound 12b is 
40-fold more potent than the amide-linked 7, despite their similar linker length. Relative to the 
standard SAHA, 12c, the most potent compound in this series, is 70-fold more potent (Table 
5.1).  The foregoing results showed that these conjugates followed a trend similar to that which 
we noted for the previously reported, structurally unrelated, triazole-based HDACi (48). 
To obtain evidence for the HDAC isoform selectivity, we tested these dual acting Topo II 
–HDACi conjugates against selected recombinant HDACs – HDAC 1, HDAC 6 and HDAC 8.  
The pattern of the anti-HDAC activities of these compounds against HDAC 1 and HDAC 6 is 





Specifically, compounds 7 and 12b have indistinguishable activity against HDAC 1 and HDAC 
6 (Table 5.1).  Additionally, 12a which has mid-nanomolar IC50 against HeLa cell nuclear 
extract HDACs is almost inactive against HDAC 1 (IC50 = 4.6 µM) while it maintains decent 
activity against HDAC 6  (IC50 = 0.6 µM).  We are not exactly sure of the cause of this disparity.  
In general, these compounds are weaker inhibitors of HDAC 8 with the exception of 7, whose 
anti-HDAC 8 activity is only about 4-fold less than its anti-HDAC 1 activity (Table 5.1).  These 
data suggest that 7 is a more indiscriminate inhibitor of these sets of HDACs while the rest of the 






Table 5.1 In vitro HDAC Inhibition.  
Compound n 
















SAHA - 65.0 38± 2 27± 2 1989± 156 
DAU - N.D. N.T. N.T. N.T. 
7 - 64.7 47± 3 20± 1 220±21 
12a 1 89.9 4,600± 240 555± 36 N.D. 
12b 2 1.6 54± 3 30± 2 4,129±421 
12c 3 0.9 8± 0.4 20± 0.4 710± 43 
12d 4 4.2 11± 0.4 19± 1 379±37 
aInhibition was assayed using the Biomol HDAC Fluorimetric Assay/Drug Discovery Kit.   







5.4 In vitro Topoisomerase II Decatenation 
 
We performed a cell-free DNA decatenation assay to determine the Topo II inhibition 
activity of these Topo II-HDACi conjugates.  We used kinetoplast DNA (KDNA), a catenated 
network of mitochondrial DNA seen in trypanosomes, to quantify the conjugates’ Topo II 
inhibition activity according to a literature protocol (49-50). The substrate KDNA (200ng) and 
50µM drug were combined in assay buffer (50 mM Tris–HCl, pH 8, 120 mM KCl, 10 mM 
MgCl2, 0.5 mM ATP, 0.5 mM dithiothreitol, 300ug/ml bovine serum albumin (BSA)) and 
incubated for 10 min on ice.  Next, 1 U of topoisomerase II was added and the reaction was 
allowed to proceed for 10 min at 37°C.  The reaction was quenched via the addition of loading 
buffer (1% sarkosyl, 0.025% bromophenol blue, and 5% glycerol), and was then analyzed by 
electrophoresis on a 1% agarose gel in TBE buffer (89 mM Tris, 89 mM borate, and 2 mM Na–
EDTA, pH 8.3) for 3.5 h at 40 V.  The gel was stained with SYBR Green I (Molecular Probes) 
for 30 min and was visualized under UV illumination and photographed on an AlphaImager. 
Figure 5.4 illustrates the results obtained from this study.  KDNA and decatenated 
KDNA marker (lanes 1 and 2 respectively) were used as controls.  Treatment of KDNA with 
Topo II within 10 min at 37°C resulted in an extensive DNA decatenation (lane 3).  As expected, 
addition of 50 µM DAU to the decatenation experiment resulted in a severe impairment of DNA 
decatenation (comparing lanes 3 and 4).  Relative to DAU, 12a and 12d have lower Topo II 
inhibition activity, with the worst overall inhibition shown by 12a, the conjugate with a four 
methylene linker (lanes 7 and 8).  Conjugates 12b and 7 inhibited Topo II activity at comparable 
levels to that of DAU at the same drug concentration (lanes 6 and 9, respectively).  However, 





total inhibition at 50 µM (comparing lanes 4 and 5).  These results show that the Topo II 
inhibition activity of DAU is tolerant of an appropriate attachment of HDACi groups and, as in 
the case of 12c, such groups could further enhance Topo II inhibition activities of anthracycline 
derivatives.  The molecular basis of the HDACi linker length-dependent enhancement of Topo II 
inhibition of these dual-acting conjugates isn’t entirely clear.  It is plausible that the placement of 
the HDACi group of these conjugates within DNA minor grooves, through the daunosamine 
sugar could further promote drug-DNA association, thereby enhancing the stability of the 
biologically relevant drug-DNA-Topo II ternary complex (51).   
 
 
Figure 5.4 Topoisomerase II Decatenation Assay. Lanes 1-3:  (1) KDNA, (2) decatenated 
KDNA marker, (3) KDNA and Topo II.  Lanes 4-9:  KDNA, Topo II, and 50µM (4) DAU, (5) 






5.5 In Vitro Cell Growth Inhibition 
 
Cell viability experiments were performed to probe for the prospect of biological activity 
of these compounds in the cellular milieu.  DU-145 prostate carcinoma and SK-MES-1 non-
small cell lung carcinoma was obtained from ATCC and maintained in the recommended growth 
mediums.  MCF-7 breast cancer cells were a generous gift from Dr. Donald Doyle.  All cell lines 
were maintained in a 37°C incubator with a 5% CO2 environment.  All compounds to be tested 
were dissolved to a concentration of 10 mM in DMSO and stored at -80°C.  Cells were passaged 
24 h prior to cell viability experiments.  For cancer cell viability experiments, cells were dosed 
for 72 h and viability was determined both by Trypan Blue staining and through the use of the 
MTS assay (Promega) according to manufacturer’s instructions.  Control wells were dosed with 
fresh media containing 0.1% DMSO. 
Three human cancer cell lines were used to quantify IC50 values for these compounds.  
Table 2 shows the IC50 values of each compound for all cancer cell types studied.  The positive 
control compounds DAU and SAHA inhibit the proliferation of these tumor cell lines with IC50 
similar to the values in the literature (52-53). DAU displays cell line dependent cytotoxicity that 
varies by as much as 10-fold among these three cell lines while SAHA shows no such cell line 
dependent effect (Table 5.2).  Bifunctional compounds 12a-d show linker length dependent anti-
proliferative activities that closely matched their anti-HDAC activities.  Among the three 
transformed cell lines investigated, these compounds decreased the viability of DU-145 the most, 
while they are least cytotoxicity against MCF-7.  Although less pronounced than that seen with 
DAU, these compounds display cell line-dependent cytotoxicity as well.  Nevertheless, the 





is the dominating mode of antiproliferative activities of compounds 12a-d.  Specifically, the anti-
proliferative activities of 12c and SAHA, compounds with similar linker length, are virtually 
indistinguishable against DU-145 and SK-MES-1 cell lines.  This finding is surprising since 12c 
displays the most potent HDAC and Topo II inhibition activities.  Interestingly, compound 7, a 
true hybrid between SAHA and DAU, showed the best cytotoxicity of all the bifunctional 
compounds across all cell lines, possessing sub-micromolar activities.  In fact, the cytotoxicity of 
7 closely rivals that of DAU, and they are equipotent against MCF-7.  This is contrary to the 
trend seen in the cell-free assays.  The potentiation of the activity of 7 within the cellular 
environment could be due to many factors, including the predominance of the Topo II inhibition 
character in dictating the bioactivity of 7, the indiscriminate inhibition of multiple HDAC 







Table 5.2 Cell Viability Assay.aValues are the average of two experiments performed in 











5.6 Intracellular Topoisomerase II Inhibition 
 
To obtain information about the intracellular fate of Topo II upon cell exposure to these 
dual-acting agents, we used an immunoblotting kit to assay compound-induced Topo II 
inhibition in an intracellular environment (Figure 5.5) (54). DU-145 cells were dosed with drug 
concentrations corresponding to cell growth inhibition IC50’s while the control cells were dosed 
with vehicle (0.1% DMSO). The relative levels of stabilized Topo II-DNA cleavage complexes 
were determined for a 30 min drug treatment, as described by the manufacturer.  Within this 
period, the control cells showed no significant amounts of Topo II inhibition, evidenced by the 
low levels of Topo II associated DNA (Figure 7a, lane 1). Cells treated with DAU and 12b 
contained high levels of Topo II – DNA cleavage complexes, with 12b showing a significantly 
higher amount (Figure 7a - lanes 2 and 4, respectively). This result suggests that 12b could 
derive its cytotoxic activity, in part, from intracellular Topo II inhibition. Conversely, the levels 
of Topo II – DNA cleavage complexes in cells exposed to 7 is indistinguishable from that of the 
control cells (Figure 7, lane 3), suggesting a minimal contribution of Topo II inhibition to the 
cytotoxic activity of 7 within this period.  
To elucidate any contribution Topo II inhibition could be adding to long-term inhibition 
of cell proliferation, Topo II cleavage complexes were assayed after 72 hours of treatment with 
compounds (Figure 7b).  DU-145 cells were probed for Topo II inhibition with an in vitro 
blotting kit designed to show relative amounts of stabilized Topo II-DNA cleavage complexes 
(Topoisomerase II In Vivo Link Kit, Topogen).  Briefly, cells were dosed with Topo II-HDACi’s 
at concentrations pertaining to their respective IC50 values for cell viability inhibition.  Control 





recommended in the protocol instructions, cells were dosed for 30 minutes, counted, and lysed 
with 1% sarkosyl.  Alternately, DU-145 cells were dosed for 72 hours, counted, and equalized 
with the cell count from the 30 min incubation before subsequent lysis.  Lysate was collected, 
loaded on a CsCl gradient, and subjected to centrifugation at 31,000 RPM at room temperature 
for 12 hours.  Aliquots of the gradient separations were then taken and the Topo II-DNA 
cleavage complexes were identified via absorbance at 260 nm.  Aliquots were then loaded into a 
slot blotting device and subjected to vacuum to load proteins onto a nitrocellulose membrane.  
Immunoblotting using the Odyssey Imaging System (LiCor Biosciences) revealed Topo II levels 
associated with the stabilized DNA complexes. 
As expected, DAU treatment results in significant inhibition of Topo II activity relative to 
control levels (Figure 5.5b, comparing lanes 1 and 2). Compound 7 shows a measured increase in 
Topo II inhibition relative to control levels (Figure 7b, comparing lanes 1 and 3). Interestingly, 
we observed a drastic drop in the levels of stabilized Topo II-DNA cleavage complexes upon cell 
exposure to 12b for 72-hour (comparing lane 4 of Figures 5.5a and 5.5b). This result suggests 
that the Topo II inhibition activity of 7 increases with time while that of 12 decreases. The 
persistence of the stabilized Topo II-DNA cleavage complexes over a longer period indicates 
that Topo II inhibition may contribute significantly to the mechanism of the antiproliferative 









Figure 5.5 Intracellular Topo II Inhibition.  DU-145 cells were probed for stabilized DNA-Topo 
II cleavage complexes upon (a) 30 min treatment; (b) 72 hour treatment with bifunctional 









5.7 Cellular Localization 
 
HDAC1 and Topo II, are cell nucleus-localized targets of these bifunctional compounds, 
while HDAC6 is cytoplasmic.  To probe if cell penetration issues could be one of the alternative 
reasons for the difference in the potencies of compounds 7 and 12b, we used confocal 
microscopy to visualize their intracellular localization (Figure 8).  Cells were plated on glass 
coverslips in 35mm dishes 24 h before the experiment.  They were then incubated with fresh 
media containing the indicated compounds at concentration of 1 µM.  After 4 hours, cells were 
washed with PBS   Cover slips were then mounted and viewed under a confocal microscope 
(DAU λex = 488nm,; Zeiss LSM 510 UV confocal microscope). We exposed DU-145 cells to 1 
µM of DAU, 7 and 12b.  After 4 hours incubation time, cells were monitored at 488nm, the 
excitation wavelength (λex) of DAU, and we observed clear differences in the intracellular 
distribution profiles of the tested compounds.  In agreement with previous study in the literature, 
DAU is localized within the nuclear and perinuclear regions of DU-145 cells (55).  Although it 
shows a less nuclear localization, compound 7 is more widely distributed within the cytosol with 
evidence for perinuclear localization in similar to that of DAU.  In contrast, 12b shows a highly 
diminished intracellular distribution with the bulk of the compound trapped in vesicle-like bodies 
within the cell (Figure 5.6).  The relatively poor intracellular distribution of 12b could be due to 
low cell membrane penetration or an enhanced pump-induced efflux of compound from within 
the cell (56). We obtained a similar result with a lung tumor derived A549 cells (supporting 
information Figure S1). These results show that 7 and 12b have different intracellular residency 
which may affect access to their targets and consequently offer additional insight into underlying 








Figure 5.6 Cellular Localization of Dual-Acting Inhibitors.  (a) DAU, (b) 7, (c) 12b.  DU-145 









5.8 Interaction of Topo II/HDAC Inhibitor Conjugates with DNA and RNA 
 
 
 In an attempt to better understand the results of the in vitro and in vivo experiments 
detailed above, it was next investigated how the changes to the classic anthracycline 
pharmacophore in the conjugate TopoII/HDACi molecules altered their ability to bind to nucleic 
acid targets. A 32-mer RNA and DNA hairpin construct of the same sequence  
5`-GCUCUCUGCGAACUCGUAAGAGGAGGUAUAGGGAGC-3` and  
5`-GCTCTCTGCGAACTCGTAAGAGGAGGTATAGGGAGC-3` were used in melting 
experiments and fluorescence quenching experiments to determine the affinity of the novel 
compounds for nucleic acids (Figure 5.7). These constructs were designed to include many of the 
representative small molecule binding structural motifs found in nucleic acids including a helical 
region, mismatch pair, internal bulge and loop regions as well as a tetraloop. 
 
                              








UV-vis melting experiments 
UV melting experiments were performed in the absence of drug and in the presence of 
drug at a final concentration of 20 µM while the concentration of DNA or RNA was held 
constant at 2.5 µM. Nucleic acid and drug complexes were formed by the addition of an aliquot 
of stock drug solution in DMSO to a volume of DNA or RNA in BPE buffer (6mM Na2HPO4, 
2mM Na2H2PO4, 1mM EDTA, pH 7.1). The mixture was allowed to equilibrate for at least 20 
min at 4°C to ensure complete association. The drug stock was prepared so that upon reaching 
the desired concentration of drug, the amount of DMSO in the sample was no >1% of the total 
volume. Melting studies were performed over a temperature range of 25–90°C, using a melting 
rate of 1°C/min and data were collected every half degree. In order to favor hairpin formation 
and avoid self-association, constructs were heated at 99°C for 1 min, then slowly cooled 
(1°C/min) to 10°C prior to being melted from 25°C to 90°C (57). For melting experiments, 
absorbance was measured at 260 nm, and the temperature was controlled with a Quantum 
Northwest TC 125 temperature control unit. The Tm was taken as the midpoint of the melting 
transition as determined by the maxima of first derivative plots. All Tms were reproducible to 
within ±1°C. Repeated recording of heating and cooling profiles indicates that no hysteresis 
occurs in the absence or presence of ligand. Results of the melting studies including change in 
melting temperature (Tm) as well as change in Tm (∆Tm) for DNA and RNA can be found in 









Fluorescence quenching experiments 
Quenching of the drugs’ natural fluorescence upon binding to DNA was monitored via 
titrations of a constant concentration of drug (7 µM) with DNA of increasing concentration (0.1–
7 µM). Quenching experiments were performed in a 96-well black microplate following the 
protocol described by Hergenrother et al. (58). Fluorescence emission at 556nm was recorded on 
a Molecular Devices SpectraMAX Gemini microplate reader after excitation at 485nm. All 
experiments were repeated at least four times. The data collected in the fluorescence quenching 
titrations was fit to the linear Stern-Volmer equation (59): 
Io / I = 1 + Ksv * [Q] 
Where Io is the fluorescence intensity of drug in the absence of quencher, I is the fluorescence 
intensity after introduction of quencher, Ksv is the slope of the linear fit and Stern-Volmer 
constant, and [Q] is the concentration of quencher, in this case DNA. Stern-Volmer constants for 
DAU and all conjugate compounds can be found in Table 5.3. Stern-Volmer plots for all 










Table 5.3 Melting temperature, shift in melting temperature, and Stern-Volmer constants for all 
compounds and DNA. 
 
  Tm ∆Tm Ksv (µmol
-1
) 
No Drug 38.3 N/A N/A 
20 µM DAU 64.5 26.3 13 
20 µM 7 62.2 23.9 8.0 
20 µM 12a 42.2 3.9 2.0 
20 µM 12b 41.5 3.3 0.58 
20 µM 12c 52.0 13.8 0.21 







Table 5.4 Melting temperature and shift in melting temperature for all compounds and RNA. 
  Tm ∆Tm 
No Drug 51.6 N/A 
20 µM DAU 56.0 4.4 
20 µM 7 52.1 0.5 
20 µM 12a 52.1 0.5 
20 µM 12b 53.4 1.8 
20 µM 12c 52.0 0.4 



















 There is evidence for the synergistic effect of combined Topo II and HDAC inhibitors on 
cancer (38).  However, this synergy is schedule dependent, hence traditional combination therapy 
involving Topo and HDAC inhibitors may be complicated by the inherent pharmacokinetic 
disadvantage of two separate drugs.  To critically delineate the benefits of simultaneous Topo 
and HDAC inhibition in cancer therapy, it will be of interest to identify agents that possess Topo 
and HDAC inhibition activities within a single molecule. Toward this goal, we have rationally 
designed, successfully synthesized, and extensively characterized a novel class of Topo II / 
HDAC inhibitor conjugates joining the parent molecules of DAU and SAHA in two unique 
fashions. These conjugates were demonstrated to retain the activity of both parent molecules to 
some degree. In vitro HDAC inhibition assays showed that compound 7 most closely mirrored 
the inhibitory profile of SAHA while compound 12a was shown to be the worst inhibitor. 
Compounds 12b-12d displayed an impressive increase in HDAC inhibition of isoforms 1 and 2 
(Table 5.1). All compounds were shown to retain Topo II inhibition through an in vitro KDNA 
decatenation assay (Figure 5.4). Compound 12b was more potent than even DAU at inhibiting 
Topo II, and 12a was the least effective inhibitor.  
 Whole cell viability assays demonstrated that with the retention of parent molecule 
activity came the retention of antiproliferative ability (Table 5.2). Compound 7 showed an 
incredibly potent inhibitory profile like DAU, while compounds 12a-12d most imitated the 
profile of SAHA. It is this in vivo assay of activity that is most telling about the mode of action 
of the conjugates in that 7 most likely relies heavily on its DAU-like moiety to inhibit growth  





assay showed compound 7 was unable to poison Topo II by stalling it in the cleavable ternary 
complex with itself and DNA (Figure 5.5 column 3), it has been demonstrated that this poisoning 
event is not necessary to retain topo II inhibition in vivo and is variable amongst cell lines (REF). 
Fluorescence microscopy studies further showed 7 to be a viable drug in that its localization in 
the cell most closely resembled DAU while 12b seemed to suffer from poor uptake or an efflux 
mechanism (Figure 5.6). 
To further characterize the novel TopoII / HDAC inhibitors, their ability to bind to 
nucleic acids was assessed in both a DNA and RNA hairpin target. The change in melting 
temperature observed after the binding of a small molecule drug to DNA can be used to assess 
the affinity of the molecule for its nucleic acid target (59). Table 5.3 shows that all conjugates 
retain the ability to bind to DNA to some extent. However, a drastic difference can be seen with 
the binding affinities of 7 and 12d closely mimicking that of DAUthe (nearly identical ∆Tm) 
while 12c induced a median shift in Tm. Compounds 12a and 12b caused minimal perturbation to 
Tm showing that their ability to bind to DNA has been severely hindered. This trend reveals that 
the amide linker of 7 is well tolerated, possibly allowing the daunosamine sugar to maintain its 
role in the minor groove interaction that compliments the DNA base-pair intercalative interaction 
of the aromatic aglycone portion of the anthracycline molecule. Interestingly, the data suggest 
that the triazole linker hinders the daunosamine sugar minor groove interaction when the linker 
length is too short. As evidenced by the increase in ∆Tm of 12d, DNA binding capability is 
restored with a long enough linker. This is undoubtedly due to the inherent flexibility of a longer 
linker, yielding a more plastic nature of the tail moiety upon intercalation. In agreement with this 
are the Stern-Volmer constants derived for these compounds while binding to DNA (Table 5.4). 





quencher. In this case the quencher is DNA and the quenching mechanism is attributed to the 
intercalation of the fluorophoric anthracycline ring system. Thus it is no surprise that DAU has 
the largest Ksv (13 µmol
-1) followed most nearly by 7 (8.0 µmol-1) and next by 12d (5.1 µmol-1). 
The DNA target proved to be a poor quencher of compounds 12a-c as evidenced by the flatness 
of their respective Stern-Volmer plots (Figure 5.8). This is likely attributable to the conjugates 
reduced ability to bind the DNA construct used in this study. However, when considered with the 
relatively large ∆Tm of 13.8 °C, the relatively small Ksv value of 12c stands out. This would 
suggest that tail portion of the molecule is able to add to the overall binding ability via optimal 
positioning of hydrogen bond participants with respect to the minor groove. 
Through melting studies performed with an RNA hairpin target, it was determined that 
the conjugates did not possess the parent DAU molecule’s ability to bind to ribonucleic acid 
(Table 5.4). With the possibly detrimental interaction of anthracyclines with IRE RNA detailed 
in chapter 2 of this thesis, it would be of tremendous interest to see if there is any change in the 
deleterious side effects of these novel conjugates that seem to lack the ability to bind to RNA.  
With the vast compliment of data presented to characterize the biological activity of the 
novel conjugates synthesized in this work, it is clear that each compound presents its own 
repertoire of affinities and activities. It is this uniqueness that warrants the future study of all of 
the compounds presented here in more complex biological systems. 
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CHAPTER 6: MOLECULAR ARCHITECTURE OF ZINC BINDING 
SMALL MOLECULES THAT INHIBIT SPLICESOME ASSEMBLY 
 
This work was published by Vishal Patil, Joshua Canzoneri, Timur R. Samatov, Reinhard 





The removal of intervening sequences (introns) from a primary RNA transcript is 
catalyzed by the spliceosome, a large ribonucleoprotein complex. At the start of each splicing 
cycle the spliceosome assembles anew on the pre-mRNA intron to be removed, in a sequentially 
ordered manner. We describe here the identification of a series of naphthalen-2-yl hydroxamate 
compounds that inhibit pre-mRNA splicing in vitro with mid- to high-micromolar values of IC50. 
These hydroxamates stall the spliceosome assembly at the “A complex” stage. A structure–
activity analysis on lead compounds revealed three pharmacophores that are essential for splicing 
inhibition. Specifically, a hydroxamate as a zinc-binding group and a 6-methoxynaphthalene cap 
group are both critical, and a linker chain comprising 8–9 methylene groups is also important, for 
the specific binding to the docking site of target protein molecule and precise positioning of the 
zinc binding group. As we found no correlation between the inhibition patterns of known histone 
deacetylases on the one hand and pre-mRNA splicing on the other, we conclude that these 
compounds may function through the inhibition of the activities of other, at present, unknown 
spliceosome-associated zinc metalloprotein(s). 
The removal of introns from a primary RNA transcript is catalyzed by a large RNP 
complex termed the spliceosome. This is a highly complex and dynamic RNP machine. It is 
composed of the five snRNPs U1, U2, U4, U5, and U6 and a large number of non-snRNP 
proteins (Wahl et al., 2009). Spliceosomes assemble in a stepwise manner and thus pass through 





A complex. Subsequently, the U4/U6.U5 tri-snRNP associates, and the precatalytic B complex is 
generated. After major rearrangements resulting in the displacement of U1 and U4, the activated 
spliceosome (Bact) is formed, followed by additional restructuring and catalysis of step 1 of 
splicing. This involves cleavage at the 5’ splice site of the pre-mRNA and the ligation of the 5’ 
end of the intron to the so-called branch site to form a lariat-like structure. This leads to 
formation of the spliceosomal C complex, which catalyzes step 2 of splicing, during which the 
intron is excised and the exons are ligated together to form mRNA. After this the spliceosome 
dissociates and the snRNPs are recycled for additional rounds of splicing. 
Aberrant pre-mRNA splicing is associated with many human diseases, including 
cancer, neurodegenerative and autoimmune diseases, making the spliceosome a highly attractive 
drug target (Tazi et al., 2005b). Small molecules arresting spliceosome assembly at defined 
points would also be of great use for the detailed investigation of the structure and function of 
the spliceosome. 
To date, only a limited number of small-molecule inhibitors of pre-mRNA splicing 
have been identified. These include antibiotics (erythromycin, Cl-tetracycline, and streptomycin) 
(Hertweck et al., 2002), a biflavonoid (isoginkgetin) (O’Brien et al., 2008), inhibitors of the 
kinase activity of topoisomerase I (Pilch et al., 2001; Tazi et al., 2005a), antitumor drugs 
targeting the U2 snRNP Spliceostatin A (Kaida et al., 2007) and pladienolide (Kotake et al., 
2007), selected inhibitors of histone deacetylases and histone acetyltransferases (Kuhn et al., 
2009), lichen secondary metabolites (Samatov et al., 2012) and 1,4-naphthoquinones and 1,4-
heterocyclic quinones with known anticancer activity (Berg et al., 2012). The specific 
spliceosome targets have been identified for only a few of those compounds. The lack of clear 






Several spliceosome-associated proteins possess potential enzymatic activities whose 
function in the splicing reaction remains unclear (Rappsilber et al., 2002; Zhou et al., 2002; 
Hartmuth et al., 2002; Jurica and Moore, 2003; Deckert et al., 2006). For example, numerous 
peptidyl–prolyl isomerases have been found, even though it is not clear whether the isomerase 
activity is required at all, or whether their domains are involved in protein–protein interactions. 
In addition, many proteins exhibit zinc-binding motifs, suggesting that zinc ions may have 
functional and/or structural roles in splicing (Rappsilber et al., 2002; Zhou et al., 2002; Jurica 
and Moore, 2003; Agafonov et al., 2011). Additionally, the activity of histone deacetylases 
(HDACs), which are classical zinc metalloproteases, has been shown to be important for splicing 
catalysis, although their precise functions in the splicing process are not clear (Hnilicova et al., 
2011). In fact, zinc depletion by the chelator 1,10-phenanthroline (1,10-phe) has been shown to 
inhibit the second step of splicing (Shomron et al., 2002). It has been demonstrated that specific 
zinc-chelating agents that perturb protein acetylation state (through inhibition of HDACs 
activity) block the splicing cycle (Kuhn et al., 2009). The exact relationship between zinc 
chelation, protein acetylation state and splicing reaction integrity was not clear from that study, 
as only a limited set of HDAC inhibitors (HDACi) was screened. In the present work, we sought 
to clarify this relationship by screening a HDACi library that was structurally more diverse 
(Canzoneri et al., 2009; Chen et al., 2008; Mwakwari et al., 2010a; Mwakwari et al., 2010b; 
Oyelere et al., 2009; Patil et al., 2010). We report here the elucidation of unique molecular 
features that confer splicing inhibition upon zinc-chelating agents with HDACi activity. Native 
gel analysis of the spliceosome assembly revealed that it is inhibited at an early stage, and the 





and the splicing-inhibition activities of these compounds suggests that the primary target(s) of 
their splicing inhibition are not HDACs. However, the existence of certain similarities does 







6.2 Screening of Structurally Diverse HDACi for Splicing Inhibition 
Earlier work had demonstrated the presence of HDACs in purified population of 
spliceosome (Rappsilber et al., 2002; Zhou et al., 2002; Gunderson et al., 2011), and on this basis 
we previously investigated the prospect of splicing inhibition by selected HDACi (Kuhn et al., 
2009). These HDACi inhibited splicing with sub- to low-millimolar values of IC50 (the 
concentration giving 50% inhibition). However, there was no clear evidence linking the effects 
of these HDACi on splicing with their actual HDAC inhibition, especially as their IC50 values in 
splicing were found to be several orders of magnitude higher than the reported values for HDAC 
inhibition. HDAC has 18 known isoforms, organized into four different classes. Classes I, II, and 
IV depend on a catalytic zinc ion and differ in their cellular location, while Class III HDACs 
require NAD+ (Ropero and Esteller, 2007). The prototypic pharmacophore for HDACi consists 
of three distinct structural motifs: a recognition cap group, a hydrophobic linker, and the zinc-




Figure 6.1 The prototypic pharmacophore for histone deacetylase inhibitors (here SAHA), 
which typically is comprised of three distinct structural motifs: a recognition cap group, a 






The HDACi recognition cap group moieties undergo interaction with amino-acid residues on the 
surface of HDACs and present excellent opportunities for the selective modulation of their 
biological activities (Mwakwari et al., 2010b). We surmised that profiling the splicing inhibition 
activities of HDACi that differ in respect of their three distinct structural motifs might help us to 
discern possible links between HDAC inhibition and inhibitory effects on the splicing reaction. 
To this end, we first screened a small (63-member), yet structurally diverse HDACi library (See 
Supplemental Table S1 for the structures) at 100 µM using a conventional in vitro splicing assay. 
The HDACi activity of compounds in the screened library against HDAC1 and HeLa cell nuclear 
extract HDACs ranges from single digit- to mid-nanomolar (Canzoneri et al., 2009; Chen et al., 
2008; Mwakwari et al., 2010a; Oyelere et al., 2009; Patil et al., 2010). Despite their potency, 
these HDACi did not broadly inhibit splicing. We identified only two compounds – 6-
methoxynaphthalen-2-yl hydroxamates 24 and 25 that noticeably inhibit splicing at 100 µM (Fig. 
6.2). The structures of these compounds are almost identical, differing only in the length of a 
hydrophobic linker, 6 methylene groups for 24 and 7 for 25. More detailed investigation revealed 
that these compounds inhibit pre-mRNA splicing with the same efficiency (Fig. 2B). Complete 
inhibition of splicing was observed at 150 µM (Fig. 2B, lanes 4 and 8), with an IC50 value of 







Figure 6.2  Hit compounds 24 and 25 inhibit pre-mRNA splicing in vitro and lead to an 
accumulation of spliceosome assembly intermediates: (A) Structures of the compounds. (B) 
Increasing concentrations of compounds 24 and 25 were tested for their effect on the splicing of 
32P-labeled MINX pre-mRNA. After splicing, the radiolabeled RNA was analyzed by denaturing 
PAGE followed by autoradiography. The leftmost lane shows the DMSO control experiment. 
Compound numbers are shown in the top panel, and drug concentrations tested are shown 
immediately below the compound numbers. The positions of lariat-intron, pre-mRNA, fully 
spliced mRNA, and 5’-exon (top to bottom) are indicated on the left. (C) Formation of splicing 
complex on 32P-labeled MINX pre-mRNA in the presence of 250 µM of the respective 
compounds. Reactions were stopped at the time points indicated, and the products were analyzed 
on a native agarose gel. Bands were visualized by phosphor imaging. The positions of the 





Table 6.1 Structure–activity relationships of the splicing inhibition activities of 
6-methoxynaphthalen-2-yl hydroxamates. aCited from refs (Chen et al., 2008; Patil et al., 2010) – 
activities against HeLa nuclear extract (HDAC 1 & 2). NT, not tested; NI, no significant 
inhibition (below 20%). % HDAC inhibition activities of the compounds at 10 µM are given if 
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To determine at which stage splicing complex formation is inhibited, we performed a 
splicing time-course experiment. The spliceosomal complexes formed were analyzed by native 
agarose gel electrophoresis. After 2 min of splicing, predominantly A and B complexes were 
visible in the DMSO control (Fig. 6.2C, lane 2). After 7 min, most A complexes had been 
converted into B complexes, which were in turn converted into later complexes (Bact, C) after 20 
min. After 60 min only small amounts of the A, Bact and C were still visible (lanes 3-5). In the 
presence of 250 µM of compound 24 or 25, the kinetics of splicing complex assembly appeared 
similar to each other and differed dramatically from those in a DSMO control (Fig. 6.2C, lanes 
6-15). Mainly A complexes accumulated at all of the time points analyzed. Thus, the formation 
of B complexes is inhibited, indicating that one or more protein factors required for it are 
inactivated by these compounds. Besides, the amount of stalled A complexes was significantly 
lower than in the DMSO control reaction (compare the 2-minute time point, lane 2). This 
indicates that the formation of A complexes is compromised by these HDACi. These data imply 
that potential targets of the compounds are also among the proteins needed for assembly of the A 
complex. Remarkably, compound 24 has an HDACi activity 15 times higher than that of 
compound 25 (Table 6.1; Patil et al., 2010), yet both compounds stalled the spliceosome 
assembly to about the same extent. Another intriguing observation is the fact that compound 9 
(Supplemental Table S1), an analog of 24 with a single methylene chain deletion, and a more 
than 8-fold stronger HDACi than 24 (Chen et al., 2008), was not identified as a splicing inhibitor 
in the primary screen. These data, together with the fact that only two structurally related 
compounds have been identified among the 63 diverse potent HDAC inhibitors, suggest that the 






The screening of the HDACi library (Oyelere et al., 2009; Patil et al., 2010) for splicing 
inhibition identified 6-methoxynaphthalen-2-yl hydroxamates 24 and 25 as small molecules that 
inhibit splicing in a specific context. Both compounds inhibit spliceosome assembly at an early 
stage, to about the same extent, with IC50 values close to 130 µM (Table 6.1). These data 
provided the initial indication that the inhibition of splicing may be not due to HDAC targets. To 
investigate this question further we carried out a detailed structure–activity analysis of the 
compounds. We synthesized a series of structural analogs of compounds 24 and 25 and tested 
their effect on the in vitro splicing of 32P-labeled MINX pre-mRNA as well as their HDAC 
inhibition activity against representative class I and class II HDAC isoforms – HDAC1, HDAC6 
and HDAC8. First, we investigated the length of a hydrophobic linker between a recognition cap 
and zinc-binding groups. Compounds 24 and 25 have 6- and 7-methylene chain linkers, 
respectively (Table 6.1). A shorter version present in the initial compound collection, with 5 
methylene groups, was filtered out as inactive against splicing (compound 9, Supplemental Table 
S1). We experimented with introducing longer linkers. Indeed, the single (compound 67a) as 
well as the double (compound 67b) methylene chain extensions significantly increased the 
potency (Table 6.1). Further increase in the length resulted in compounds that were less active, 
67c and the slightly less potent 67d (although these were still almost as potent as the lead 
compounds 24 and 25). Thus there is a correlation between the anti-splicing activity and the 
length of the linker, with an optimum number of methylene groups of 8 and 9. As for the HDACi 
activity, compounds 67a and 67b inhibited HDAC1 and HDAC6 with mid-nanomolar IC50s and 
were completely inactive against HDAC8, while 67c potently inhibited HDAC6 and HDAC8 





inhibition activity; it was found to be inactive against HDAC1 and HDAC6 and weakly active 
against HDAC8, yet it showed significant inhibition of splicing. 
Another structural motif of the pharmacophore that we investigated was the 
naphthalene cap group. The substitution of 6-methoxy moiety by a protic electron-donating 
group such as OH or NH2 is detrimental to the function of the compounds, as these changes 
abolished splicing inhibitory activity (Table 6.1; compare 70b and 70c with 24; 70d with 25). In 
contrast, compounds 70b, 70c and 70d were found to be broadly active against the HDAC 
isoforms tested, with single-digit nanomolar to mid-nanomolar IC50s against HDAC1 and 
HDAC6. The observation that there is no correlation between anti-HDAC and anti-splicing 
activities of these molecules supports the suggestion that the targets of these compounds in 
splicing are not HDACs. Besides, these data suggest that the naphthalene cap group needs to be 
specifically recognized by the target protein(s). It is noteworthy that compounds 74a and 74b – 
with a single methylene extension of the naphthalene cap 6-ether moiety compared with 25 and 
67b, respectively – possess almost the same splicing inhibitory activity as the initial molecules. 
To investigate the role of zinc chelation in the splicing-inhibitory activity of these 
naphthalene-2-yl hydroxamates, we synthesized methyl esters 80 and 81, and carboxamide 82. 
These compounds are the derivatives of the hydroxamates 24 and 67b. As expected, all of these 
non-hydroxamate analogs lacked HDAC-inhibition activity. Significantly, they also failed to 
inhibit splicing in vitro (Table 6.1). These results indicate that zinc coordination is important for 
both anti-HDAC and anti-splicing activities. An add-back experiment was performed to test 






Figure 6.3 Relieving the inhibitory effect of the compound 67b. Radiolabeled MINX pre-
mRNA was incubated in nuclear extract under standard splicing conditions in the presence of 
DMSO (lanes 1–6) or semi-inhibitory 100 µM concentration of the compound 67b (lanes 7–12) 
and the indicated concentrations of ZnCl2 added at the indicated reaction time points. After 
splicing, the radiolabeled RNA was analyzed by denaturing PAGE followed by autoradiography. 
The positions of lariat-intron, pre-mRNA, and fully spliced mRNA (top to bottom) are indicated 




The indicated concentrations of ZnCl2 were added at the beginning of the splicing reaction 
(addition time 0 min, odd lanes) or after 1 h incubation (addition time 60 min, even lanes), 
followed by another 60 min incubation under splicing conditions. The addition of 30 and 100 
µM ZnCl2 to the control reaction with DMSO had little effect on splicing, although the pre-
mRNA substrate appeared to be slightly stabilized in some cases (lanes 1-6). The splicing 





compounds described here (lanes 7 and 8). Addition of 30 µM ZnCl2 before initiation of the 
splicing reaction, did not reverse inhibition by 67b, whereas addition of 100 µM ZnCl2 restored 
splicing efficiency to near control levels (lanes 9 and 11). Addition of 100 µM ZnCl2 also led to 
a general increase in the amount of the splicing substrate, but the observed increase in the 
splicing products is not due solely to this apparent stabilization effect. Interestingly, addition of 
ZnCl2 to the inhibited splicing reaction 1 h later had no effect (lanes 10 and 12). These data 
suggest that compound 67b irreversibly inhibits splicing; once it binds to its target protein and 
chelates its zinc ion, the inhibitory effect, which could potentially involve a structural change in 
the targeted protein, can no longer be reversed by exogeneously added zinc ions. In contrast, 
allowing compound 67b to bind zinc prior to interacting with its target protein, neutralizes its 
inhibitory effect, presumably by preventing 67b from removing the zinc that is normally bound 
by its target protein. This result confirms the principal role of zinc chelation in the mechanism of 
action of the compounds described. However, one should note the dramatic difference between 
the effects observed here, and those of the zinc chelation by 1,10-phe, which requires millimolar 
concentrations and results in the reversible inhibition of the step 2 of splicing (Table 6.1; 







All three structural motifs of the pharmacophore for HDACi exhibit a synergistic 
activity, as the cap group and linker are both important for the specific binding to the docking 
site of the target protein molecule and precise positioning of the zinc-binding group for effective 
zinc chelation. The SAR analysis of the compounds identified that inhibit splicing reveals that all 
three groups are important for splicing inhibition activity, though to different degrees: the intact 
zinc-binding group is absolutely essential, and the naphthalene cap group is also important; the 
hydrophobic linker has a more pronounced length restriction in that linkers with 8 and 9 
methylene groups confer the highest activity upon the compounds. Taken together, our data 
suggest that splicing inhibition involves not only the interaction of the inhibitor with one or more 
splicing factor, but also, that its zinc binding group is positioned close to zinc binding group of 
the target protein, leading to chelation of its zinc. They furthermore suggest that the target 
proteins are not HDACs. In fact, there are a number of spliceosomal proteins that contain zinc 
finger motifs and associate with different complexes during the spliceosome assembly pathway 
(Rappsilber et al., 2002; Zhou et al., 2002; Agafonov et al., 2011; Jurica and Moore, 2003; 
Bessonov et al., 2008; Bessonov et al., 2010). Their detailed biochemical function is not yet 
clear, and they could well be targets of the compounds presented here. Our future work will 
include the affinity labeling of these compounds, which it is hoped will aid the identification of 








6.4 Materials and Methods 
HDAC Assay Inhibition 
In vitro HDAC inhibition was assayed using the HDAC Fluorimetric Assay/Drug 
Discovery Kit as previously described (Chen et al., 2008; Mwakwari et al., 2010a; Oyelere et al., 
2009). Briefly, 15 µL of HeLa nuclear extract was mixed with 5 µL of 10× compound and 5 µL 
of assay buffer.  Fluorogenic substrate (25 µL) was added, and reaction was allowed to proceed 
for 15 min at room temperature and then stopped by addition of a developer containing TSA. 
Fluorescence was monitored after 15 min at excitation and emission wavelengths of 360 and 460 
nm, respectively. IC50 values were determined using logit plots. Assays of HDAC1, HDAC6 and 
HDAC8 activity were performed according to the manufacturer’s instructions. 
 
Splicing substrates, reactions, and spliceosome complex analysis 
Uniformly 32P-labeled, m7G(5’)ppp(5’)G-capped MINX pre-mRNA was synthesized 
in vitro by T7 runoff transcription. Splicing reactions contained 30% (v/v) HeLa nuclear extract 
in buffer D [20 mM HEPES-KOH at pH 7.9, 100 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA, 
20% (v/v) glycerol, 0.5 mM DTT, 0.5 mM PMSF], 25 mM KCl, 3 mM MgCl2, 20 mM creatine 
phosphate, 2 mM ATP, 3 nM 32P-labeled pre-mRNA, 2.5% (v/v) DMSO, and the indicated 
concentration of the chemicals tested for their effect on splicing. For the analysis of the splicing 
products, the reactions were stopped after 60 min incubation at 30 ºC; RNA was isolated by 
proteinase K treatment, phenol extraction, and ethanol precipitation; separated by denaturing 
polyacrylamide gel electrophoresis on an 7 M urea / 14% (w/v) polyacrylamide gel; and 
visualized by phosphor imaging (Typhoon 8600, GE Healthcare). For the analysis of the 





[1× TBE, 30% (v/v) glycerol, 1.25 mg/mL heparin] at the time points indicated, and the mixture 
was then placed on ice. Complexes were separated on 1.5% (w/v) agarose gels. 
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The work completed in this thesis will provide the foundation for a wide array of future 
studies in the lab of Dr. Oyelere. Novel compounds presented here were designed, synthesized, 
characterized and their biological targets were validated. This is just the beginning of 
understanding the potential of each novel class of molecules. For example, the anthracycline 
derivative topoisomerase II / histone deacetylase inhibitor conjugates, with their differential 
mode of nucleic acid binding, may prove to have a unique side effect profile in a therapeutic 
application. The peptolide probe family of molecules will also be further investigated. As for the 
currently synthesized peptolides, future studies could involve their ability to overcome antibiotic 
resistant strains of prokaryotes due to the vast increase of binding area compared to macrolides 
alone. As a result of the observation of this thesis work that some peptolides posses eukaryotic 
translation inhibition capabilities, they could also prove to be useful in preventing the growth of 
rapidly proliferating eukaryotic cells such as plasmodium, leishmania, or tumor cells. 
Additionally, different head groups could be used in createing new peptolides; for example, an 
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Fig. S1 UV-vis melting curves of ferritin H-chain IRE RNA in the absence (solid) and presence 
(dashed) of A) 20 µM DOX and B) 20 µM DAU and first derivative plots H-chain IRE RNA in 


































































Fig. S2 Overlay of the melting profiles of (A) TAR mRNA and (B) TAR C22U mRNA in the 









































Fig S3 Job plots for: (A) U6C, U10C Ferritin H-chain IRE RNA double mutant, and (B) U10C 
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Fig. S4 Cleavage band validation autoradiograph.   Lane: (1) Ladder of 16-poly -U and 23-poly-
U RNA constructs. (2) Ferritin H-chain IRE RNA only. (3) Ferritin H-chain IRE RNA and 20 
µM DOX after T1 digestion.  The 16-poly-U and 23-poly-U bands are adjacent to the cleavage 
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5 µM 
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20 µM 
DOX 47.9 43.6 42.5 55.6 49.0 45.0 60.5 
        
5 µM 
DAU 38.5 37.0 36.0 50.5 44.0 40.0 55.5 
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Figure S5 First derivative plots of UV melting profiles for construct G23I and A) No drug, B) 5 
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Overlay of the melting profiles of G23I mRNA (A) in the absence (solid) and presence (dashed) 










Rank 6  Eqn 8107  Decay2Hyp(a,b,c)
r^2=0.98885847  DF Adj r^2=0.9846804  FitStdErr=0.03086137  Fstat=399.39433
a=0.043094624 b=0.90437496 
c=2.0365862 





























Rank 7  Eqn 8107  Decay2Hyp(a,b,c)
r^2=0.985365  DF Adj r^2=0.97987687  FitStdErr=0.032720735  Fstat=302.98199
a=0.071053071 b=0.83736994 
c=2.0415214 
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Rank 7  Eqn 8107  Decay2Hyp(a,b,c)
r^2=0.99422491  DF Adj r^2=0.99205926  FitStdErr=0.022010012  Fstat=774.7093
a=0.063319142 b=0.90321042 
c=1.2202217 





























Rank 8  Eqn 8107  Decay2Hyp(a,b,c)
r^2=0.99828094  DF Adj r^2=0.99763629  FitStdErr=0.013234923  Fstat=2613.2043
a=-0.0064014186 b=0.99046862 
c=1.559148 
































Rank 12  Eqn 8107  Decay2Hyp(a,b,c)
r^2=0.9882828  DF Adj r^2=0.98388885  FitStdErr=0.038537391  Fstat=379.55068
a=-0.029003557 b=1.0990706 
c=1.5713262 

































Chapter 5 Supporting Information  
 
 
Cellular Localization of Dual-acting Inhibitors in A549 cells 
 
   
Figure B1.  Cellular Localization of Dual-Acting Inhibitors.  (A) DAU, (B) 7, (C) 12b.  A549 
cells were dosed at 1µM for 4 hours with indicated compounds and visualized by confocal 
microscopy. 
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